
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">



<head id="Head1"><meta name="google-site-verification" content="_VGwTV0Z3wNC7pQw33rX86U_BGdiQMqGvEu9XPCrV54" />
                
    <!--MOBIFY - DO NOT ALTER - PASTE IMMEDIATELY AFTER OPENING HEAD TAG -->
    <style type="text/css">
        .bannerTopo {
            width: 100%;
            height: auto;
            float: left;

        }
        .colorbox_login {
        }
    </style>
    
    <script type="text/javascript">
        /*<![CDATA[*/
        (function (n, p) {
            function d(a) {
                if (a.mode) {
                    var b = c("mobify-mode");
                    b && a[b] || (b = a.mode(l.ua));
                    return a[b]
                }
                return a
            }

            function g() {
                function a(b) {
                    n.addEventListener(b, function () {
                        l[b] = +new Date
                    }, !1)
                }
                n.addEventListener && (a("DOMContentLoaded"), a("load"))
            }

            function h() {
                var a = new Date;
                a.setTime(a.getTime() + 300000);
                p.cookie = "mobify-path=; expires=" + a.toGMTString() + "; path=/";
                n.location.reload()
            }

            function k() {
                e({
                    src: "https://preview.mobify.com/v7/"
                })
            }

            function c(a) {
                if (a = p.cookie.match(RegExp("(^|; )" + a + "((=([^;]*))|(; |$))"))) {
                    return a[4] || ""
                }
            }

            function f(a) {
                p.write('<plaintext style="display:none">');
                setTimeout(function () {
                    m.capturing = !0;
                    a()
                }, 0)
            }

            function e(j, o) {
                var i = p.getElementsByTagName("script")[0],
                    a = p.createElement("script"),
                    b;
                for (b in j) {
                    a[b] = j[b]
                }
                o && a.setAttribute("class", o);
                i.parentNode.insertBefore(a, i)
            }
            var m = n.Mobify = {},
                l = m.Tag = {};
            m.points = [+new Date];
            m.tagVersion = [7, 0];
            l.ua = n.navigator.userAgent;
            l.getOptions = d;
            l.init = function (b) {
                l.options = b;
                if ("" !== c("mobify-path")) {
                    if (g(), b.skipPreview || "true" != c("mobify-path") && !/mobify-path=true/.test(n.location.hash)) {
                        var i = d(b);
                        if (i) {
                            var a = function () {
                                i.post && i.post()
                            };
                            b = function () {
                                i.pre && i.pre();
                                e({
                                    id: "mobify-js",
                                    src: i.url,
                                    onerror: h,
                                    onload: a
                                }, "mobify")
                            };
                            !1 === i.capture ? b() : f(b)
                        }
                    } else {
                        f(k)
                    }
                }
            }
        })(window, document);
        (function () {
            var b = "//cdn.mobify.com/sites/onofre-mobile/production/adaptive.min.js";
            Mobify.Tag.init({
                mode: function (a) {
                    return /^((?!windows\sphone).)*(ip(hone|od)|android.*(mobile)(?!.*firefox))/i.test(a) ? "enabled" : "desktop"
                },
                enabled: {
                    url: b
                },
                desktop: {
                    capture: !1,
                    url: "//a.mobify.com/onofre-mobile/a.js"
                }
            })
        })(); /*]]>*/
    </script>
    <!-- END MOBIFY -->
    <script language="javascript" type="text/javascript">window.chaordic_meta = { "page": { "name": "product", "timestamp": new Date(),"selected_specs": {"sales_channel": "24"},"categories": [{"name": "Medicamentos","id": "55"},{"name": "Hipoglicemiante","id": "234","parents": ["55"]}]},"product": {"id": "625","name": "Actos 30mg Com 15 Comprimidos","url": "/actos-30mg-com-15-comprimidos/625/05","description": "Cloridrato de Pioglitazona","images": {"300x300": "https://www.onofre.com.br/img/Busca/imagem_prescricao.jpg"},"categories": [{"name": "Medicamentos","id": "55"},{"name": "Hipoglicemiante","id": "234","parents": ["55"]}],"installment": {"count": 1,"price":38.42},"extra_info": {"otc": "yes"},"details": {"rating": {"total": "0","value": "0",},"codigo_interno": "047457","registro_ms": "1055302380046","volume": "0","quantidade": "0","generico": "nao","consulta_genericos": "True","programa_beneficio": "False","marca": "Abbott","urlMarca": "/busca/0/0/0/0/2658/0/0/08"},"old_price": 49.26,"price": 38.42,"ean_code": "7891158042294","brand": "Abbott","status": "available","skus": [{"sku": "047457","specs": {"sales_channel": "12"},"price": 38.42,"old_price": 49.26,"installment": {"count": 1,"price":38.42},"status": "unavailable"},{"sku": "047457","specs": {"sales_channel": "20"},"price": 58.22,"old_price": 73.74,"installment": {"count": 1,"price":58.22},"status": "unavailable"},{"sku": "047457","specs": {"sales_channel": "8"},"price": 55.31,"old_price": 73.74,"installment": {"count": 1,"price":55.31},"status": "unavailable"},{"sku": "047457","specs": {"sales_channel": "27"},"price": 55.98,"old_price": 74.64,"installment": {"count": 1,"price":55.98},"status": "unavailable"},{"sku": "047457","specs": {"sales_channel": "34"},"price": 55.98,"old_price": 74.64,"installment": {"count": 1,"price":55.98},"status": "unavailable"},{"sku": "047457","specs": {"sales_channel": "38"},"price": 55.98,"old_price": 74.64,"installment": {"count": 1,"price":55.98},"status": "unavailable"},{"sku": "047457","specs": {"sales_channel": "737"},"price": 58.22,"old_price": 74.64,"installment": {"count": 1,"price":58.22},"status": "unavailable"},{"sku": "047457","specs": {"sales_channel": "750"},"price": 58.22,"old_price": 74.64,"installment": {"count": 1,"price":58.22},"status": "unavailable"},{"sku": "047457","specs": {"sales_channel": "783"},"price": 58.22,"old_price": 73.74,"installment": {"count": 1,"price":58.22},"status": "unavailable"},{"sku": "047457","specs": {"sales_channel": "18"},"price": 38.42,"old_price": 50.49,"installment": {"count": 1,"price":38.42},"status": "available"},{"sku": "047457","specs": {"sales_channel": "24"},"price": 38.42,"old_price": 49.26,"installment": {"count": 1,"price":38.42},"status": "available"},{"sku": "047457","specs": {"sales_channel": "144"},"price": 38.42,"old_price": 49.26,"installment": {"count": 1,"price":38.42},"status": "available"}],"specs": {"sales_channel": ["12","20","8","27","34","38","737","750","783","18","24","144"]}}}</script>
    <!--Script Chaordic Loader-->
    <script async defer src="//static.chaordicsystems.com/static/loader.js" data-apikey="onofrefarma"></script>
    <!--<script type="text/javascript"> var headID = document.getElementsByTagName("head")[0]; var newScript = document.createElement('script'); newScript.type = 'text/javascript'; newScript.src = '//static.chaordicsystems.com/static/loader.js'; newScript.setAttribute('data-apikey', 'onofrefarma'); newScript.async = true; newScript.defer = true; headID.appendChild(newScript); </script> -->
    <!--Script Chaordic Loader - FIM -->
    <meta name="viewport" content="width=device-width, initial-scale=1.0" /><meta http-equiv="X-UA-Compatible" content="IE=8" /><title>
	Actos 30mg Com 15 Comprimidos | Onofre 
</title>

    <script src="Jss/gaEventos.js"></script>
    <link type="image/x-icon" href="https://www.onofre.com.br/favicon.ico" rel="icon" /><link type="image/x-icon" href="https://www.onofre.com.br/favicon.ico" rel="SHORTCUT ICON" />
        <!-- CSS -->
        <link href="/Jss/Colorbox/colorbox.css" rel="stylesheet"/>
<link href="/Jss/ToolTip/bubbletip/bubbletip.css" rel="stylesheet"/>
<link href="/Jss/ToolTip/bubbletip/bubbletip-IE.css" rel="stylesheet"/>
<link href="/Css/resetNovo.css" rel="stylesheet"/>
<link href="/Css/star_rating.css" rel="stylesheet"/>
<link href="/Css/EstiloMasterNovo.css" rel="stylesheet"/>
<link href="/Css/MasterNova.css" rel="stylesheet"/>
<link href="/shadowbox/shadowbox.css" rel="stylesheet"/>
<link href="/Css/rodape.css" rel="stylesheet"/>
<link href="/Css/EstiloExtraBucks.css" rel="stylesheet"/>
<link href="/assets/css/base.css" rel="stylesheet"/>
<link href="/assets/css/common.css" rel="stylesheet"/>

        <link href="/Css/AutenticacaoPBM.css" rel="stylesheet" />
        <!-- CSS -->
        <!-- JSS -->
        <script src="/Jss/jquery_onofre.js"></script>
<script src="/Jss/jquery.maskMoney.js"></script>
<script src="/shadowbox/shadowbox.js"></script>
<script src="/Jss/jquery.cookie.js"></script>
<script src="/Jss/Colorbox/jquery.colorbox-min.js"></script>
<script src="/Jss/Dialog/jquery-ui-1.10.1.custom.min.js"></script>
<script src="/Jss/generic.js"></script>
<script src="/Jss/jqzoom.pack.1.0.1.js"></script>
<script src="/Jss/jquery.hoverIntent.minified.js"></script>
<script src="/Jss/ToolTip/jQuery.bubbletip-1.0.6.js"></script>
<script src="/Jss/ToolTip/ToolTip.js"></script>
<script src="/assets/js/lib/owl.carousel.min.js"></script>
<script src="/assets/js/main.js"></script>
<script src="/Jss/Utils/MasterPage.js"></script>

        <script src="/Jss/AutenticaFloatBar.js"></script>
        <link href="/Css/select2.min.css" rel="stylesheet" />
        <script src="/Jss/Utils/select2.min.js"></script>
        <link href="/Css/MasterResponsivo.css" rel="stylesheet" />
        <script src="/Jss/Utils/Home.js"></script>
        <script type="text/javascript" src='https://www.google.com/recaptcha/api.js'></script>
        <!-- JSS -->
    
    <!--[if lt IE 9]> <script src="https://html5shim.googlecode.com/svn/trunk/html5.js"></script> <![endif]-->
    <!-- JSS -->
    
    
    
    <script type='text/javascript' src='https://v2.afilio.com.br/mastertag.php?progid=1719&type=product&id_partner=drogariaonofre&product_id1=625&id_category=0&stock=0&product_sku=&product_name=ACTOS 30MG 15S&product_desc=Actos 30mg Com 15 Comprimidos&product_photo=https://www.onofre.com.br/estatico/Produto/Normal/&price1=38,42&price2=49,26&product_currency=BRL&url_product=http://www.onofre.com.br/DetalheProduto/Default.aspx?ProductName=actos-30mg-com-15-comprimidos&ProductId=625'></script>
    <link href="/Css/EstiloDetalheProduto.css" rel="stylesheet"/>
<link href="/Css/jqzoom.css" rel="stylesheet"/>
<link href="/Jss/Colorbox/colorbox.css" rel="stylesheet"/>
<link href="/assets/css/prateleira.css" rel="stylesheet"/>
<link href="/assets/css/produto.css" rel="stylesheet"/>
<script type="text/javascript" src="/Jss/DetalheProduto.js" defer></script>
<script type="text/javascript" src="/Jss/jqzoom.pack.1.0.1.js" defer></script>
<script type="text/javascript" src="/Jss/zoom/jquery.jqzoom-core.js" defer></script>
<script type="text/javascript" src="/jss/zoom/zoom.js" defer></script>
<script type="text/javascript" src="/Jss/Colorbox/jquery.colorbox-min.js" defer></script>
<script type="text/javascript" src="/Jss/Utils/DetalheProduto.js" defer></script>
<script type="text/javascript" src="/assets/js/produto.js" defer></script>

    <script type="text/javascript">        /*<![CDATA[*/ var dataLayer = [{
                               'site' : { 'domain' : document.location.host },
                               'page' : { 
                                            'name' : document.title,
                                            'pageType' : 'product'
                                        },
                                               'product' : {
                                               'productName' : 'ACTOS 30MG 15 S',
                                               'productId' : '625',
                                               'productCategory' : '',
                                               'productSubCategory' : '',
                                               'productPrice' : '38.42',
                                               'productBrand' : 'Abbott'
                                           },
                               'session' : {
                                                'isLogged': false,
                                                'user' : { 'id' : 'VISIT-1050533183' }
                                           }
                                }];; /*]]>*/ </script>
<link rel="stylesheet" type="text/css" href="//onofre.resultspage.com/autocomplete/sli-rac.css" /><meta name="description" content="Actos 30mg Com 15 Comprimidos da Abbott com o menor preço é na Onofre. Receba seu pedido em casa pagando em até 3x. Compre agora!" /></head>
            

<body id="body" class="produto">

    <!-- BANNER TOPO -->
    
    <div class="bannerTopo" style="max-height: 100px">
        
    </div>
    <!-- FIM - BANNER TOPO -->
    <script type="text/javascript" src="//onofre.resultspage.com/autocomplete/sli-rac.config.js"></script>
    
    <!-- Start Alexa Certify Javascript -->
    <script type="text/javascript" src="https://d31qbv1cthcecs.cloudfront.net/atrk.js"></script>
    <script type="text/javascript">
        _atrk_opts = {
            atrk_acct: "xfCse1aALO00g7",
            domain: "onofre.com.br"
        };
        atrk();
    </script>
    <noscript>
        <img src="https://d5nxst8fruw4z.cloudfront.net/atrk.gif?account=xfCse1aALO00g7" style="display: none" height="1" width="1" alt="" />
    </noscript>
    <script type="text/javascript">
        /* Set the width of the side navigation to 250px */
        function openNavMobile() {
            document.getElementById("mySidenav").style.width = "255px";
        } /* Set the width of the side navigation to 0 */
        function closeNavMobile() {
            document.getElementById("mySidenav").style.width = "0";
        }
    </script>
    <!-- End Alexa Certify Javascript -->
    <form method="post" action="/actos-30mg-com-15-comprimidos/625/05" id="form1">
<input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="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" />

<script> ECO_Step='Product';</script><script> ECO_DepName='';</script><script> ECO_DepId='';</script><script> ECO_CatName='';</script><script> ECO_CatId='';</script><script> ECO_ProdName='actos-30mg-com-15-comprimidos';</script><script> ECO_ProdId='625';</script><script> ECO_ProdValue='38.42';</script><script> ECO_ProdSumValue='38.42';</script><script> ECO_ProdQty='1';</script><script> ECO_ProdAvgValue='38,42';</script>
<script type="text/javascript">
//<![CDATA[
products = []; products.push( {'id':047457,'name':'Actos 30mg Com 15 Comprimidos','category':'Hipoglicemiante','price':38.42,'quantity':0,'brandId':2658});var productData ={   'transaction': {'id':0,     'products': products}};//]]>
</script>

<script src="/ScriptResource.axd?d=BnWrJ6-gLV3GlI8g28LCzYXkfKJLttyoigz0AJpfnvO4NN21YTBbDD9JctBIuGGW8YufhqFw-AnVHbmyWvfFb_B2w9DMLRk3OO9iqYmkxfGcvnVf4ImxaGFLKlWYiwlxPddzmc-9JHkJ8clChxff5mADpJw1&amp;t=42a7acab" type="text/javascript"></script>
<input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="53BE6E71" />
<input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAA5k3EOt/lPykXbU988SIPPVvGJREAXUqdHbn/uqryQegasCjseFQU1IG6a1QV/1IsPDvqD576IjU8b+VycT56M9ED22EwkGKj1YkpT+X+kXiM56f9BvruTcOsm75dsnP4j+rR3kChNt2jv+P1A6lf1Kfh0m/YFL+gqaOapTOLGCT3uEmapvkS7PnXX2p48aV5JXiYT1tmrUuDA14lwoxMmxwwFaVvdlxqKyIPzmKQOht10zlZ50n5/bgpryiq8TYbTiGFmIzfo9yGe+bEAzvUUqpn81zJ0Z0QXvC4qr7fLDbTeSrVy7MrFa5Tndb4qqDarbbEAN" />
        
        <!-- Master -->
        
        <!-- Header -->
        <div id="mySidenav" class="sidenav">
            
            <a href="javascript:void(0)" id="divMobileLogin"><span style="float: left; font-size: 18px; text-decoration: underline" onclick="window.location.href='https://www.onofre.com.br/acesso/'">Faça o login ou cadastre-se</span>
                <br />
                <span class="closebtn" onclick="closeNavMobile()">&times;</span></a>
            <!--<a href="#">About</a> <a href="#">Services</a> <a href="#">Clients</a> <a href="#">Contact</a>-->
            <hr />
            <nav id="mobile-nav" class="page-nav">
                                    <div class="wrapper full">
                                        <ul class="nav-list">
                                            <li class="medicamentos-e-saude"><a onclick="$('.medicamentos-e-saude .sub-nav').toggle();" title="Medicamentos" class="nav-link">Medicamentos</a>
                                                <div class="sub-nav">
                                                    <ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Intestino e Digestão</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/saude-digestiva/44/03' class='medi-sub-nav-link' >Saúde Digestiva</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiflatulento/54/03' class='medi-sub-nav-link' >Antiflatulento</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiacido/95/03' class='medi-sub-nav-link' >Antiácido</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/laxante/248/03' class='medi-sub-nav-link' >Laxante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Diabetes</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/hipoglicemiante/234/03' class='medi-sub-nav-link' >Hipoglicemiante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Hormônios</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antigotoso/57/03' class='medi-sub-nav-link' >Antigotoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/tireoidiano/342/03' class='medi-sub-nav-link' >Tireoidiano</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Infecções</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antibiotico/32/03' class='medi-sub-nav-link' >Antibiótico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-infeccioso/67/03' class='medi-sub-nav-link' >Anti-infeccioso</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Aparelho Urinário</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antidiuretico/46/03' class='medi-sub-nav-link' >Antidiurético</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antilitiasico/80/03' class='medi-sub-nav-link' >Antilitiásico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/diuretico/190/03' class='medi-sub-nav-link' >Diurético</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/incontinencia-urinaria/242/03' class='medi-sub-nav-link' >Incontinência Urinária</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Nervoso</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antivertiginoso/112/03' class='medi-sub-nav-link' >Antivertiginoso</a></li><li class='medi-sub-nav-item'><a href='/homeopaticos/calmante/147/03' class='medi-sub-nav-link' >Calmante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disturbio-do-tubo-neural/188/03' class='medi-sub-nav-link' >Distúrbio do Tubo Neural</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/neuropsicoestimulante/278/03' class='medi-sub-nav-link' >Neuropsicoestimulante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Gripe e Resfriado</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antitussigenos/109/03' class='medi-sub-nav-link' >Antitussígenos</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/descongestionante/179/03' class='medi-sub-nav-link' >Descongestionante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/irritacoes-da-garganta/246/03' class='medi-sub-nav-link' >Irritações da Garganta</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/expectorante-e-mucolitico/274/03' class='medi-sub-nav-link' >Expectorante e Mucolítico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Anti-Hipertensivo</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiarritmico/27/03' class='medi-sub-nav-link' >Antiarritmico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-hipertensivo/62/03' class='medi-sub-nav-link' >Anti-hipertensivo</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/cardiotonico/149/03' class='medi-sub-nav-link' >Cardiotônico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hipertensor/231/03' class='medi-sub-nav-link' >Hipertensor</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Cuidado com os Olhos</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/orgaos-sensoriais/56/03' class='medi-sub-nav-link' >Órgãos Sensoriais</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/descongestionante-ocular/180/03' class='medi-sub-nav-link' >Descongestionante Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/distrofia-do-globo-ocular/189/03' class='medi-sub-nav-link' >Distrofia do Globo Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/lubrificante-ocular/260/03' class='medi-sub-nav-link' >Lubrificante Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Circulatório</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antianemico/26/03' class='medi-sub-nav-link' >Antianêmico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-hemorragico/61/03' class='medi-sub-nav-link' >Anti-hemorrágico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antivaricoso/111/03' class='medi-sub-nav-link' >Antivaricoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hemostatico/221/03' class='medi-sub-nav-link' >Hemostático</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Vermes e Parasitas</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antifungico/52/03' class='medi-sub-nav-link' >Antifúngico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antimalarico/81/03' class='medi-sub-nav-link' >Antimalárico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiparasitario/90/03' class='medi-sub-nav-link' >Antiparasitário</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Dor e Febre</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/analgesico/8/03' class='medi-sub-nav-link' >Analgésico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anestesico/13/03' class='medi-sub-nav-link' >Anestésico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antienxaquecoso/48/03' class='medi-sub-nav-link' >Antienxaquecoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-inflamatorio/69/03' class='medi-sub-nav-link' >Anti-inflamatório</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Alergias</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antialergico/21/03' class='medi-sub-nav-link' >Antialérgico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Respiratório</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiasmatico/29/03' class='medi-sub-nav-link' >Antiasmático</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/broncodilatador/142/03' class='medi-sub-nav-link' >Broncodilatador</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Pele e Mucosa</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/cicatrizante/155/03' class='medi-sub-nav-link' >Cicatrizante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/despigmentante/182/03' class='medi-sub-nav-link' >Despigmentante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/aftas/215/03' class='medi-sub-nav-link' >Aftas</a></li><li class='medi-sub-nav-item'><a href='/tratamento-rosto/antiacne/399/03' class='medi-sub-nav-link' >Antiacne</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Vitaminas e Suplementos</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antifadiga/53/03' class='medi-sub-nav-link' >Antifadiga</a></li><li class='medi-sub-nav-item'><a href='/nutricosmeticos/antioxidante/88/03' class='medi-sub-nav-link' >Antioxidante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/orexigeno/281/03' class='medi-sub-nav-link' >Orexígeno</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/vitaminico/367/03' class='medi-sub-nav-link' >Vitamínico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Saúde Masculina</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antialopecia/20/03' class='medi-sub-nav-link' >Antialopécia</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiandrogenico/24/03' class='medi-sub-nav-link' >Antiandrogénico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disfuncao-eretil/185/03' class='medi-sub-nav-link' >Disfunção Erétil</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hiperplasia-prostatica-benigna/230/03' class='medi-sub-nav-link' >Hiperplasia Prostática Benigna</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Saúde Feminina</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/anticoncepcionais/39/03' class='medi-sub-nav-link' >Anticoncepcionais</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disturbio-do-ciclo-menstrual/187/03' class='medi-sub-nav-link' >Distúrbio do Ciclo Menstrual</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/indutor-da-ovulacao/243/03' class='medi-sub-nav-link' >Indutor da Ovulação</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/terapeutica-da-menopausa/337/03' class='medi-sub-nav-link' >Terapêutica da Menopausa</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Ósseo</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiartrosico/28/03' class='medi-sub-nav-link' >Antiartrósico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiosteoporotico/87/03' class='medi-sub-nav-link' >Antiosteoporótico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/osteoporose/94/03' class='medi-sub-nav-link' >Osteoporose</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/repositor-de-potassio/315/03' class='medi-sub-nav-link' >Repositor de Potássio</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Controle Especial</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antidepressivo/42/03' class='medi-sub-nav-link' >Antidepressivo</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiparkinsoniano/91/03' class='medi-sub-nav-link' >Antiparkinsoniano</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Outros</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antineoplasico/84/03' class='medi-sub-nav-link' >Antineoplásico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antitabagismo/103/03' class='medi-sub-nav-link' >Antitabagismo</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul>
                                                         </div>
                                            </li>
                                            <li class="medicamentos-e-saude_new"><a onclick="$('.medicamentos-e-saude_new .sub-nav').toggle();" title="Saúde" class="nav-link">Saúde</a>
                                                <div class="sub-nav">
                                                    <ul class="sub-nav-col">
                                                        <li class='sub-nav-item'><a href='/geriatria/46/01' class='sub-nav-link' title='Geriatria'>Geriatria</a></li><li class='sub-nav-item'><a href='/higiene-e-limpeza/48/01' class='sub-nav-link' title='Higiene e Limpeza'>Higiene e Limpeza</a></li><li class='sub-nav-item'><a href='/homeopaticos/50/01' class='sub-nav-link' title='Homeopáticos'>Homeopáticos</a></li><li class='sub-nav-item'><a href='/alimentos-e-bebidas/52/01' class='sub-nav-link' title='Alimentos e Bebidas'>Alimentos e Bebidas</a></li><li class='sub-nav-item'><a href='/medicamentos/55/01' class='sub-nav-link' title='Medicamentos'>Medicamentos</a></li><li class='sub-nav-item'><a href='/cuidado-com-os-olhos/57/01' class='sub-nav-link' title='Cuidado com os Olhos'>Cuidado com os Olhos</a></li><li class='sub-nav-item'><a href='/ortopedia-e-acessorios/58/01' class='sub-nav-link' title='Ortopedia e Acessórios'>Ortopedia e Acessórios</a></li><li class='sub-nav-item'><a href='/primeiros-socorros/60/01' class='sub-nav-link' title='Primeiros Socorros'>Primeiros Socorros</a></li><li class='sub-nav-item'><a href='/sexo-seguro/61/01' class='sub-nav-link' title='Sexo Seguro'>Sexo Seguro</a></li><li class='sub-nav-item'><a href='/fitness-e-dietas/62/01' class='sub-nav-link' title='Fitness e Dietas'>Fitness e Dietas</a></li><li class='sub-nav-item'><a href='/testes-e-aparelhos/63/01' class='sub-nav-link' title='Testes e Aparelhos'>Testes e Aparelhos</a></li><li class='sub-nav-item'><a href='/vitaminas-e-naturais/65/01' class='sub-nav-link' title='Vitaminas e Naturais'>Vitaminas e Naturais</a></li>
                                                    </ul>
                                                    <div class="banner-menu">
                                                        <a id="A2"> <img id="Img2" /></a>
                                                        > </div>
                                                </div>
                                            </li>
                                            <li class="beleza-e-bem-estar"><a onclick="$('.beleza-e-bem-estar .sub-nav').toggle();" title="Beleza e Bem Estar" class="nav-link">Beleza e Bem Estar</a>
                                                <div class="sub-nav">
                                                    <ul class="sub-nav-col">
                                                        <li class='sub-nav-item'><a href='/tratamento-rosto/39/01' class='sub-nav-link' title='Tratamento Rosto'>Tratamento Rosto</a></li><li class='sub-nav-item'><a href='/cabelos/40/01' class='sub-nav-link' title='Cabelos'>Cabelos</a></li><li class='sub-nav-item'><a href='/corpo-e-banho/42/01' class='sub-nav-link' title='Corpo e Banho'>Corpo e Banho</a></li><li class='sub-nav-item'><a href='/cuidados-femininos/44/01' class='sub-nav-link' title='Cuidados Femininos'>Cuidados Femininos</a></li><li class='sub-nav-item'><a href='/cuidados-masculinos/49/01' class='sub-nav-link' title='Cuidados Masculinos'>Cuidados Masculinos</a></li><li class='sub-nav-item'><a href='/maos-e-pes/53/01' class='sub-nav-link' title='Mãos e Pés'>Mãos e Pés</a></li><li class='sub-nav-item'><a href='/maquiagem/54/01' class='sub-nav-link' title='Maquiagem'>Maquiagem</a></li><li class='sub-nav-item'><a href='/nutricosmeticos/56/01' class='sub-nav-link' title='Nutricosméticos'>Nutricosméticos</a></li><li class='sub-nav-item'><a href='/colonias/59/01' class='sub-nav-link' title='Colônias'>Colônias</a></li><li class='sub-nav-item'><a href='/tratamento-do-corpo/64/01' class='sub-nav-link' title='Tratamento do Corpo'>Tratamento do Corpo</a></li><li class='sub-nav-item'><a href='/higiene-bucal/68/01' class='sub-nav-link' title='Higiene Bucal'>Higiene Bucal</a></li><li class='sub-nav-item'><a href='/protecao-solar/69/01' class='sub-nav-link' title='Proteção Solar'>Proteção Solar</a></li>
                                                    </ul>
                                                    <div class="banner-menu">
                                                        <a id="A3"> <img id="Img3" /></a>
                                                         </div>
                                                </div>
                                            </li>
                                            <li class="mamae-e-bebe"><a onclick="$('.mamae-e-bebe .sub-nav').toggle();" title="Mamãe e Bebê" class="nav-link">Mamãe e Bebê</a>
                                                <div class="sub-nav">
                                                    <ul class="sub-nav-col">
                                                        <li class='sub-nav-item'><a href='/acessorios-infantis/37/01' class='sub-nav-link' title='Acessórios Infantis'>Acessórios Infantis</a></li><li class='sub-nav-item'><a href='/alimentos-infantis/38/01' class='sub-nav-link' title='Alimentos Infantis'>Alimentos Infantis</a></li><li class='sub-nav-item'><a href='/corpo-e-banho-infantil/41/01' class='sub-nav-link' title='Corpo e Banho Infantil'>Corpo e Banho Infantil</a></li><li class='sub-nav-item'><a href='/cuidados-com-a-mamae/43/01' class='sub-nav-link' title='Cuidados com a Mamãe'>Cuidados com a Mamãe</a></li><li class='sub-nav-item'><a href='/troca-de-fraldas/45/01' class='sub-nav-link' title='Troca de Fraldas'>Troca de Fraldas</a></li><li class='sub-nav-item'><a href='/cuidado-bucal-infantil/47/01' class='sub-nav-link' title='Cuidado Bucal Infantil'>Cuidado Bucal Infantil</a></li>
                                                    </ul>
                                                    <div class="banner-menu">
                                                        <a id="A4"> <img id="Img4" /></a>
                                                         </div>
                                                </div>
                                            </li>
                                            <li class="ofertas-e-lancamentos"><a onclick="$('.ofertas-e-lancamentos .sub-nav').toggle();" title="Ofertas e Lançamentos" class="nav-link"> Ofertas e Lançamentos</a>
                                                <div class="sub-nav">
                                                    <ul class="sub-nav-col">
                                                        <li class="sub-nav-item"><a href="/Produtos/OfertasLancamentos/oferta/66" class="sub-nav-link" title="Ofertas">Ofertas</a></li>
                                                    </ul>
                                                    <ul class="sub-nav-col">
                                                        <li class="sub-nav-item"><a href="/Produtos/OfertasLancamentos/lancamento/66" class="sub-nav-link" title="Lançamentos">Lançamentos</a></li>
                                                    </ul>
                                                    <div class="banner-menu">
                                                        <a id="A5"> <img id="Img5" /></a>
                                                         </div>
                                                </div>
                                            </li>
                                            <li class="como-comprar"><a href="https://www.onofre.com.br/Institucional/Default.aspx?InstId=251" title="Como Comprar" class="nav-link">Como Comprar</a> </li>
                                        </ul>
                                    </div>
                                </nav>
        </div>
        <header id="main-header" class="page-header">
                                <!--<div class="topbar-responsive"> <div class="wrapper-responsive full"> <div class="televendas col"> <p><span>Televendas:</span> <strong>4007-2526</strong></p> </div> <div class="social-responsive"> <ul class="social-list"> <li class="social-item"><a href="https://www.facebook.com/DrogariaOnofreOficial" class="social-link facebook" target="_blank" title="Facebook">Facebook</a></li> <li class="social-item"><a href="https://blogonofre.wordpress.com/" class="social-link beonofre" target="_blank" title="BeOnofre">BeOnofre</a></li>  </ul> </div> </div> </div>-->
                                <div class="topbar">
                                    <div class="wrapper full">
                                        <div class="welcome col" style="width: 570px; margin-top: 20px;">
                                            <!-- usuario logado-->
                                            
                                            <!-- fim usuario logado-->

                                            <!-- usuario não logado-->
                                            <div id="divTopoLogin" class="login col">
                                                <div id="Panel2" class="login-form">
	
                                                    <div style="display: none">
                                                        <label for="identificacao">Faça seu login:</label>
                                                        <input name="ctl00$TxtUsuario" type="text" id="TxtUsuario" class="campo_texto" autocomplete="off" placeholder="Digite seu email ou cpf" />
                                                    </div>
                                                    <div id="divPasswordDoLogin" style="display: none">
                                                        <label for="senha">Senha</label>
                                                        <input name="ctl00$TxtSenha" type="password" id="TxtSenha" class="campo_texto" />
                                                    </div>
                                                    
                                                    <a class="welcome-msg" style="font-size: 12px; vertical-align: middle; font-family: Tahoma"> OLÁ VISITANTE, </a> 
                                                    <a class="action-link criar-conta" style="font-size: 12px; font-family: Tahoma" id="btnBoxLogin" onclick="ExibirPopupLogin('../../../../../../../../Login/LoginBox.aspx',680,460)">FAÇA LOGIN</a> <a>|</a>
                                                    <a href="/cadastro/" class="action-link criar-conta" style="font-size: 12px; font-family: Tahoma">CRIAR CONTA</a> <a>|</a>
                                                    <div><a class="forgot-password action-link" href="#" style="font-size: 12px; font-family: Tahoma;vertical-align: middle;display: inline-block" onclick="ExibirPopup('../../../../../../../../login/ForgotPassWord.aspx',450,290)">ESQUECI MINHA SENHA</a> </div>
                                                      
</div>
                                            </div>

                                            

                               
                                           
                                        </div>
                                             <!-- fim usuario não logado -->
                                        <div class="televendas col" style="margin-top: 20px;">
                                            <p><span>Televendas:</span> <strong>4007-2526</strong></p>
                                        </div>
                                        
                                            <div class="social col" style="margin-top: 15px;">

                                                <ul class="social-list">
                                                    <li class="social-item"><a href="https://www.facebook.com/DrogariaOnofreOficial" class="social-link facebook" target="_blank" title="Facebook">Facebook</a></li>
                                                    <li class="social-item"><a href="https://www.instagram.com/drogariaonofre/" class="social-link instagram" target="_blank" title="Instagram">Instagram</a></li>
                                                    <li class="social-item"><a href="https://blogonofre.wordpress.com/" class="social-link beonofre" target="_blank" title="BlogOnofre">BeOnofre</a></li>
                                                    
                                                </ul>
                                            </div>
                                    </div>
                                </div>
                                <!-- /topbar -->
                                <div class="wrapper full">
                                    <div class="menu-responsive col" onclick="openNavMobile()"> </div>
                                    <div class="logo col">
                                        <h1>  <a href="https://www.onofre.com.br/" class="logo-img">Onofre</a>  </h1> </div>
                                    <div class="cart-responsive">
                                        <div class="cart col"> <a href="/carrinho" class="go-to-cart"><span class="total-value"> <span id="lblCartTotalResponsive">R$ 0,00</span> </span></a> </div>
                                    </div>
                                    <div class="search col">
                                        <div class="msg-cvs">
                                            <p> <img src="https://www.onofre.com.br/assets/img/cvs-health-logo.jpg" alt="CVS Health" width="105" height="21" /> A drogaria onofre agora faz parte da rede de farmácias CVS Health. <a href="https://www.onofre.com.br/Institucional/Default.aspx?InstId=230" class="action-link">Clique aqui e saiba mais.</a> </p>
                                        </div>
                                        <!-- /search -->
                                        <div class="search-box">
                                            <!-- search box starts here -->
                                            
                                         
                                             <div id="pnBuscaSli">
	
                                                <input type="hidden" name="asug"  />
                                                <input name="ctl00$sli_search_1" type="text" id="sli_search_1" data-provide="rac" value="Digite o nome do produto, marca ou princípio ativo..." class="search-field search-input" data-sli-test="searchbox" onblur="if(value==&#39;&#39;)value=&#39;Digite o nome do produto, marca ou princípio ativo...&#39;" onfocus="if(value==&#39;Digite o nome do produto, marca ou princípio ativo...&#39;)value=&#39;&#39;" onkeydown="javascript:return fnTrapKD(event,this)" autocomplete="off" /> <a id="btnOkSli" class="search-icon" href="javascript:SliSearchById('sli_search_1')" data-sli-test="searchbutton">Ok</a> 
</div>
                                          <!-- search box ends here -->
                                        </div>
                                    </div>
                                    <!-- /search -->
                                    <!-- carrinho -->
                                    <div class="cart col cart-normal"> <a href="/carrinho" class="go-to-cart"><span class="total-value"> <span id="lblShoppingCartTotal">R$ 0,00</span> </span></a>
                                        <div class="cart-hover">
                                            <div id="CartPopUp" class="cart-list">
                                                 </div>
                                            <div class="cart-bottom">
                                                <div class="line" style="display:none">
                                                     <span class="total">Total: <strong class="total-value"> <span id="lblCartTotal">R$ 0,00</span></strong></span>
                                                </div>
                                                <div class="line">
                                                    <!--<div class="one-click"><a href="" class="btn btn-gray buy-one-click">Comprar com 1 clique</a></div>-->
                                                    <div class="buy-cart"><a href="/carrinho" class="btn btn-green">Finalizar compra</a> </div>
                                                </div>
                                            </div> <span id="lblProdAdicionado" class="prod-added">Produto adicionado ao carrinho</span> </div>
                                    </div>
                                </div>
                                
                            </header>
        <nav id="main-nav" class="page-nav">
                                <div class="wrapper full">
                                    <ul class="nav-list">
                                        
                                        <li class="nav-item medicamentos-e-saude"><a href='https://www.onofre.com.br' title='Medicamentos e Saúde' class='nav-link'>Medicamentos</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Intestino e Digestão</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/saude-digestiva/44/03' class='medi-sub-nav-link' >Saúde Digestiva</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiflatulento/54/03' class='medi-sub-nav-link' >Antiflatulento</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiacido/95/03' class='medi-sub-nav-link' >Antiácido</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/laxante/248/03' class='medi-sub-nav-link' >Laxante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Diabetes</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/hipoglicemiante/234/03' class='medi-sub-nav-link' >Hipoglicemiante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Hormônios</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antigotoso/57/03' class='medi-sub-nav-link' >Antigotoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/tireoidiano/342/03' class='medi-sub-nav-link' >Tireoidiano</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Infecções</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antibiotico/32/03' class='medi-sub-nav-link' >Antibiótico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-infeccioso/67/03' class='medi-sub-nav-link' >Anti-infeccioso</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Aparelho Urinário</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antidiuretico/46/03' class='medi-sub-nav-link' >Antidiurético</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antilitiasico/80/03' class='medi-sub-nav-link' >Antilitiásico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/diuretico/190/03' class='medi-sub-nav-link' >Diurético</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/incontinencia-urinaria/242/03' class='medi-sub-nav-link' >Incontinência Urinária</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Nervoso</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antivertiginoso/112/03' class='medi-sub-nav-link' >Antivertiginoso</a></li><li class='medi-sub-nav-item'><a href='/homeopaticos/calmante/147/03' class='medi-sub-nav-link' >Calmante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disturbio-do-tubo-neural/188/03' class='medi-sub-nav-link' >Distúrbio do Tubo Neural</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/neuropsicoestimulante/278/03' class='medi-sub-nav-link' >Neuropsicoestimulante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Gripe e Resfriado</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antitussigenos/109/03' class='medi-sub-nav-link' >Antitussígenos</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/descongestionante/179/03' class='medi-sub-nav-link' >Descongestionante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/irritacoes-da-garganta/246/03' class='medi-sub-nav-link' >Irritações da Garganta</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/expectorante-e-mucolitico/274/03' class='medi-sub-nav-link' >Expectorante e Mucolítico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Anti-Hipertensivo</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiarritmico/27/03' class='medi-sub-nav-link' >Antiarritmico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-hipertensivo/62/03' class='medi-sub-nav-link' >Anti-hipertensivo</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/cardiotonico/149/03' class='medi-sub-nav-link' >Cardiotônico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hipertensor/231/03' class='medi-sub-nav-link' >Hipertensor</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Cuidado com os Olhos</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/orgaos-sensoriais/56/03' class='medi-sub-nav-link' >Órgãos Sensoriais</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/descongestionante-ocular/180/03' class='medi-sub-nav-link' >Descongestionante Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/distrofia-do-globo-ocular/189/03' class='medi-sub-nav-link' >Distrofia do Globo Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/lubrificante-ocular/260/03' class='medi-sub-nav-link' >Lubrificante Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Circulatório</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antianemico/26/03' class='medi-sub-nav-link' >Antianêmico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-hemorragico/61/03' class='medi-sub-nav-link' >Anti-hemorrágico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antivaricoso/111/03' class='medi-sub-nav-link' >Antivaricoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hemostatico/221/03' class='medi-sub-nav-link' >Hemostático</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Vermes e Parasitas</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antifungico/52/03' class='medi-sub-nav-link' >Antifúngico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antimalarico/81/03' class='medi-sub-nav-link' >Antimalárico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiparasitario/90/03' class='medi-sub-nav-link' >Antiparasitário</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Dor e Febre</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/analgesico/8/03' class='medi-sub-nav-link' >Analgésico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anestesico/13/03' class='medi-sub-nav-link' >Anestésico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antienxaquecoso/48/03' class='medi-sub-nav-link' >Antienxaquecoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-inflamatorio/69/03' class='medi-sub-nav-link' >Anti-inflamatório</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Alergias</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antialergico/21/03' class='medi-sub-nav-link' >Antialérgico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Respiratório</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiasmatico/29/03' class='medi-sub-nav-link' >Antiasmático</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/broncodilatador/142/03' class='medi-sub-nav-link' >Broncodilatador</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Pele e Mucosa</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/cicatrizante/155/03' class='medi-sub-nav-link' >Cicatrizante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/despigmentante/182/03' class='medi-sub-nav-link' >Despigmentante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/aftas/215/03' class='medi-sub-nav-link' >Aftas</a></li><li class='medi-sub-nav-item'><a href='/tratamento-rosto/antiacne/399/03' class='medi-sub-nav-link' >Antiacne</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Vitaminas e Suplementos</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antifadiga/53/03' class='medi-sub-nav-link' >Antifadiga</a></li><li class='medi-sub-nav-item'><a href='/nutricosmeticos/antioxidante/88/03' class='medi-sub-nav-link' >Antioxidante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/orexigeno/281/03' class='medi-sub-nav-link' >Orexígeno</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/vitaminico/367/03' class='medi-sub-nav-link' >Vitamínico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Saúde Masculina</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antialopecia/20/03' class='medi-sub-nav-link' >Antialopécia</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiandrogenico/24/03' class='medi-sub-nav-link' >Antiandrogénico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disfuncao-eretil/185/03' class='medi-sub-nav-link' >Disfunção Erétil</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hiperplasia-prostatica-benigna/230/03' class='medi-sub-nav-link' >Hiperplasia Prostática Benigna</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Saúde Feminina</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/anticoncepcionais/39/03' class='medi-sub-nav-link' >Anticoncepcionais</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disturbio-do-ciclo-menstrual/187/03' class='medi-sub-nav-link' >Distúrbio do Ciclo Menstrual</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/indutor-da-ovulacao/243/03' class='medi-sub-nav-link' >Indutor da Ovulação</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/terapeutica-da-menopausa/337/03' class='medi-sub-nav-link' >Terapêutica da Menopausa</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Ósseo</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiartrosico/28/03' class='medi-sub-nav-link' >Antiartrósico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiosteoporotico/87/03' class='medi-sub-nav-link' >Antiosteoporótico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/osteoporose/94/03' class='medi-sub-nav-link' >Osteoporose</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/repositor-de-potassio/315/03' class='medi-sub-nav-link' >Repositor de Potássio</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Controle Especial</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antidepressivo/42/03' class='medi-sub-nav-link' >Antidepressivo</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiparkinsoniano/91/03' class='medi-sub-nav-link' >Antiparkinsoniano</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Outros</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antineoplasico/84/03' class='medi-sub-nav-link' >Antineoplásico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antitabagismo/103/03' class='medi-sub-nav-link' >Antitabagismo</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul>
                                                     </div>
                                        </li>
                                        <li class="nav-item medicamentos-e-saude_new"><a href='https://www.onofre.com.br' title='Medicamentos e Saúde' class='nav-link'>Saúde</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class="sub-nav-col">
                                                    <li class='sub-nav-item'><a href='/geriatria/46/01' class='sub-nav-link' title='Geriatria'>Geriatria</a></li><li class='sub-nav-item'><a href='/higiene-e-limpeza/48/01' class='sub-nav-link' title='Higiene e Limpeza'>Higiene e Limpeza</a></li><li class='sub-nav-item'><a href='/homeopaticos/50/01' class='sub-nav-link' title='Homeopáticos'>Homeopáticos</a></li><li class='sub-nav-item'><a href='/alimentos-e-bebidas/52/01' class='sub-nav-link' title='Alimentos e Bebidas'>Alimentos e Bebidas</a></li><li class='sub-nav-item'><a href='/medicamentos/55/01' class='sub-nav-link' title='Medicamentos'>Medicamentos</a></li><li class='sub-nav-item'><a href='/cuidado-com-os-olhos/57/01' class='sub-nav-link' title='Cuidado com os Olhos'>Cuidado com os Olhos</a></li><li class='sub-nav-item'><a href='/ortopedia-e-acessorios/58/01' class='sub-nav-link' title='Ortopedia e Acessórios'>Ortopedia e Acessórios</a></li><li class='sub-nav-item'><a href='/primeiros-socorros/60/01' class='sub-nav-link' title='Primeiros Socorros'>Primeiros Socorros</a></li><li class='sub-nav-item'><a href='/sexo-seguro/61/01' class='sub-nav-link' title='Sexo Seguro'>Sexo Seguro</a></li><li class='sub-nav-item'><a href='/fitness-e-dietas/62/01' class='sub-nav-link' title='Fitness e Dietas'>Fitness e Dietas</a></li><li class='sub-nav-item'><a href='/testes-e-aparelhos/63/01' class='sub-nav-link' title='Testes e Aparelhos'>Testes e Aparelhos</a></li><li class='sub-nav-item'><a href='/vitaminas-e-naturais/65/01' class='sub-nav-link' title='Vitaminas e Naturais'>Vitaminas e Naturais</a></li>
                                                </ul>
                                                <div class="banner-menu">
                                                    <a id="A1"> <img id="Img1" /></a>
                                                    > </div>
                                            </div>
                                        </li>
                                        <li class="nav-item beleza-e-bem-estar"><a href='https://www.onofre.com.br' title='Beleza e Bem Estar' class='nav-link'>Beleza e Bem estar</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class="sub-nav-col">
                                                    <li class='sub-nav-item'><a href='/tratamento-rosto/39/01' class='sub-nav-link' title='Tratamento Rosto'>Tratamento Rosto</a></li><li class='sub-nav-item'><a href='/cabelos/40/01' class='sub-nav-link' title='Cabelos'>Cabelos</a></li><li class='sub-nav-item'><a href='/corpo-e-banho/42/01' class='sub-nav-link' title='Corpo e Banho'>Corpo e Banho</a></li><li class='sub-nav-item'><a href='/cuidados-femininos/44/01' class='sub-nav-link' title='Cuidados Femininos'>Cuidados Femininos</a></li><li class='sub-nav-item'><a href='/cuidados-masculinos/49/01' class='sub-nav-link' title='Cuidados Masculinos'>Cuidados Masculinos</a></li><li class='sub-nav-item'><a href='/maos-e-pes/53/01' class='sub-nav-link' title='Mãos e Pés'>Mãos e Pés</a></li><li class='sub-nav-item'><a href='/maquiagem/54/01' class='sub-nav-link' title='Maquiagem'>Maquiagem</a></li><li class='sub-nav-item'><a href='/nutricosmeticos/56/01' class='sub-nav-link' title='Nutricosméticos'>Nutricosméticos</a></li><li class='sub-nav-item'><a href='/colonias/59/01' class='sub-nav-link' title='Colônias'>Colônias</a></li><li class='sub-nav-item'><a href='/tratamento-do-corpo/64/01' class='sub-nav-link' title='Tratamento do Corpo'>Tratamento do Corpo</a></li><li class='sub-nav-item'><a href='/higiene-bucal/68/01' class='sub-nav-link' title='Higiene Bucal'>Higiene Bucal</a></li><li class='sub-nav-item'><a href='/protecao-solar/69/01' class='sub-nav-link' title='Proteção Solar'>Proteção Solar</a></li>
                                                </ul>
                                                <div class="banner-menu">
                                                    <a id="banner_menu_p2"> <img id="banner_menu_img2" /></a>
                                                     </div>
                                            </div>
                                        </li>
                                        <li class="nav-item mamae-e-bebe"><a href='https://www.onofre.com.br' title='Mamãe e Bebê' class='nav-link'>Mamãe e Bebê</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class="sub-nav-col">
                                                    <li class='sub-nav-item'><a href='/acessorios-infantis/37/01' class='sub-nav-link' title='Acessórios Infantis'>Acessórios Infantis</a></li><li class='sub-nav-item'><a href='/alimentos-infantis/38/01' class='sub-nav-link' title='Alimentos Infantis'>Alimentos Infantis</a></li><li class='sub-nav-item'><a href='/corpo-e-banho-infantil/41/01' class='sub-nav-link' title='Corpo e Banho Infantil'>Corpo e Banho Infantil</a></li><li class='sub-nav-item'><a href='/cuidados-com-a-mamae/43/01' class='sub-nav-link' title='Cuidados com a Mamãe'>Cuidados com a Mamãe</a></li><li class='sub-nav-item'><a href='/troca-de-fraldas/45/01' class='sub-nav-link' title='Troca de Fraldas'>Troca de Fraldas</a></li><li class='sub-nav-item'><a href='/cuidado-bucal-infantil/47/01' class='sub-nav-link' title='Cuidado Bucal Infantil'>Cuidado Bucal Infantil</a></li>
                                                </ul>
                                                <div class="banner-menu">
                                                    <a id="banner_menu_p3"> <img id="banner_menu_img3" /></a>
                                                     </div>
                                            </div>
                                        </li>
                                        <li class="nav-item ofertas-e-lancamentos"><a href='https://www.onofre.com.br' title ='Ofertas e Lançamentos' class='nav-link'>&nbsp&nbsp Ofertas e &nbsp&nbsp&nbsp&nbsp&nbsp<br /> &nbsp&nbsp Lançamentos</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class="sub-nav-col">
                                                    <li class="sub-nav-item"><a href="/Produtos/OfertasLancamentos/oferta/66" class="sub-nav-link" title="Ofertas">Ofertas</a></li>
                                                </ul>
                                                <ul class="sub-nav-col">
                                                    <li class="sub-nav-item"><a href="/Produtos/OfertasLancamentos/lancamento/66" class="sub-nav-link" title="Lançamentos">Lançamentos</a></li>
                                                </ul>
                                                <div class="banner-menu">
                                                    <a id="banner_menu_p4"> <img id="banner_menu_img4" /></a>
                                                     </div>
                                            </div>
                                        </li>
                                        <li class="nav-item como-comprar"><a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=251' title='Como Comprar' class='nav-link'>Como Comprar</a></li>
                                    </ul>
                                </div>
                            </nav>
        <div class="float-bar"></div>
        
        <!-- /floatbar -->
        <!-- FIM HEADER -->
        <!-- ESTRUTURA -->
        <div class="page-content">
            <div class="wrapper">
                <!-- conteudo -->
                
    <script>
  window.fbAsyncInit = function() {
    FB.init({
      appId      : '333327017122265',
      xfbml      : true,
      version    : 'v2.8'
    });
    FB.AppEvents.logPageView();
  };
</script>
    <!-- Load Facebook SDK for JavaScript -->
    <div id="fb-root"></div>
    <script>(function(d, s, id) {
      var js, fjs = d.getElementsByTagName(s)[0];
      if (d.getElementById(id)) return;
      js = d.createElement(s); js.id = id;
      js.src = "https://connect.facebook.net/pt_BR/sdk.js#xfbml=1&version=v2.8";
      fjs.parentNode.insertBefore(js, fjs);
    }(document, 'script', 'facebook-jssdk'));</script>

    <div class="page-content">
        <div class="wrapper">
            <input type="hidden" name="ctl00$cphConteudo$url" id="url" />
            <input type="hidden" name="ctl00$cphConteudo$hdAtivo" id="hdAtivo" />
            <ul class="breadcrumb full">
                <div id="breadcrumbs">
                    <a href="/Default.aspx">Drogaria Onofre</a> &#62; <a href=/medicamentos/55/01 class="bread_beleza">Medicamentos</a> &#62; <a href=/medicamentos/hipoglicemiante/234/03 class="bread_beleza">Hipoglicemiante</a>

                </div>
            </ul>
            <div class="main-product-image col9">
                <div class="main-image-wrap">
                    <!-- SELO PRODUTO -->
                    <div id="cphConteudo_seloProduto" style="background:white;border-radius:5px;color:white;text-align:center;">selo produto</div>
                    <!-- FIM SELO PRODUTO -->
                    <a href="https://www.onofre.com.br/estatico/Produto/Super/" id="cphConteudo_linkimgGrande" class="jqzoom" rel="gal1" title="">
                        <img id="cphConteudo_imgGrande" alt="Actos 30mg Com 15 Comprimidos" src="https://www.onofre.com.br/img/Busca/imagem_prescricao.jpg" height="480" width="480" />
                    </a></div>
                <input type="hidden" name="ctl00$cphConteudo$hf_id_produto" id="cphConteudo_hf_id_produto" value="625" />
                <div class="img-thumbs">
                    <ul class="thumbs-list">
                        
                    </ul>
                </div>
            </div>
            <div class="main-product-info col7">
                <div class="flags"><span class="flag entrega-4horas">
                    </span> <span class="flag uso-adulto">
                        </span> </div>
                <div class="top-infos">
                    
                    <span class="code col">
                        <span id="cphConteudo_lblCode">Cód: 047457</span></span> <span class="ms col">
                            <span id="cphConteudo_num_registro"> MS: 1055302380046</span></span> </div>
                <h1 class="main-product-name">
                    <input type="hidden" name="ctl00$cphConteudo$ProductId" id="cphConteudo_ProductId" value="625" />
                    <span id="lblProductName">Actos 30mg Com 15 Comprimidos</span></h1>
                
                <span id="cphConteudo_produtoAntibioticoAviso"></span>
                <span id="cphConteudo_listaProdutoAntbiotico"></span>
                <div class="top-infos">
                    <span id="cphConteudo_lblProductManufacturer"><a class="fabricante2" href="">Abbott</a></span>
                </div>
                <div class="product-spec">
                    <div id="DtlprinAtivo" class="spec principio-ativo">
                        <p class="spec-title col2">Princípio Ativo </p>
                        <p class="spec-text col5">
                            <span id="cphConteudo_lblDescriptionResume">Cloridrato de Pioglitazona</span>
                        </p>
                    </div>
                    
                    
                    
                    <a href="https://www.onofre.com.br/estatico/Bula/047457.pdf" id="bulaDetalhe" class="view-bula" target="_blank">Visualizar Bula do medicamento</a>
                    <div class="action-box">
                        
                        <div class="col3 dinheiro-extra" style="position: relative; margin-top: 10px;">
                            <div class="fb-save" data-uri="http://www.onofre.com.br/DetalheProduto/Default.aspx?ProductName=actos-30mg-com-15-comprimidos&ProductId=625" data-size="small"></div>
                            
                            
                            <div id="cphConteudo_divSemPBM" style="margin-top: -10px;"><small class="aviso">Preço válido para compras feitas pela internet. Imagem meramente ilustrativa.</small>
                                <!-- Campo CRM para medicamentos -->
                                <div id="cphConteudo_divCRM">
                                    <span id="cphConteudo_lblCrm">Insira o CRM do Médico:</span>
                                    <input name="ctl00$cphConteudo$txtCrm" type="text" id="cphConteudo_txtCrm" style="width: 100px; padding-bottom: -110px;" />&nbsp;
                                    <select name="ctl00$cphConteudo$slCrmUF" id="cphConteudo_slCrmUF" onchange="ValidarSelectCRM(this)">
	<option selected="selected" value="SP" disabled="">UF</option>
	<option value="AC">AC</option>
	<option value="AL">AL</option>
	<option value="AP">AP</option>
	<option value="AM">AM</option>
	<option value="BA">BA</option>
	<option value="CE">CE</option>
	<option value="DF">DF</option>
	<option value="ES">ES</option>
	<option value="GO">GO</option>
	<option value="MA">MA</option>
	<option value="MS">MS</option>
	<option value="MT">MT</option>
	<option value="MG">MG</option>
	<option value="PA">PA</option>
	<option value="PB">PB</option>
	<option value="PR">PR</option>
	<option value="PE">PE</option>
	<option value="PI">PI</option>
	<option value="RJ">RJ</option>
	<option value="RN">RN</option>
	<option value="RS">RS</option>
	<option value="RO">RO</option>
	<option value="RR">RR</option>
	<option value="SC">SC</option>
	<option value="SP">SP</option>
	<option value="SE">SE</option>
	<option value="TO">TO</option>
</select>
                                </div>
                                <!-- Fim Campo CRM para Medicamentos -->
                                <em>
                                    <span id="cphConteudo_lblMsg">Venda sob prescrição médica.</span></em> </div>

                            
                            <div id="divDescricaoDermaClub" onclick="$(this).hide();" style="width: 100%; height: 100%; position: fixed; top: 0; left: 0; background-color: rgba(255,255,255,0.6); padding-top: 10%; display: none; z-index: 5">
                                <div style="background-color: #99CCFF; border: 2px dashed #00B0F0; width: 500px; height: 250px; margin: 0 auto; color: white; font-weight: bold; z-index: 5; font-size: 19px; padding-top: 10px;"><span style="margin: 0 auto; width: 95%; display: block;">"O DermaClub é o clube de vantagens das marcas<br />
                                    La Roche-Posay, Vichy e SkinCeuticals, onde você pode acumular pontos em todas as suas compras e trocar por descontos e benefícios exclusivos. Além disso, você recebe dicas personalizadas sobre sua pele dos maiores dermatologistas do Brasil. Junte-se a nós e aproveite o máximo de vantagens para você e sua pele. Cadastre-se em <a style="text-decoration: none; color: white;" target="_blank" href="https://www.dermaclub.com.br">www.dermaclub.com.br</a>" </span></div>
                            </div>
                            <!--<div id="cphConteudo_divSeloDermaclu" onclick="window.open(&#39;/loginloreal.aspx&#39;,&#39;_self&#39;);" style="width: 225px; height: 115px; background-color: #FF7C80; padding-left: 4px; padding-right: 4px; padding-top: 4px; position: absolute; left: -65px; margin-top: 50px;">
                                <div style="background-color: white; width: 217px; height: 75px;">
                                    <div style="margin: 0 auto; width: 65%; padding-top: 12px;">
                                        <img style="float: left; margin-right: 4px;" alt="Promoção" height="24" src="/~/img/DetalheProduto/icone-medalha.png" />
                                        <img style="float: left; margin-right: 4px;" alt="DermaClub" height="13" src="/~/img/DetalheProduto/dermaclub-logo.png" />
                                        <div onmouseover="$('#divDescricaoDermaClub').show();" style="float: left; font-size: 10px; color: white; font-weight: 600; width: 12px; height: 12px; background-image: url('/~/img/DetalheProduto/interrogation-mark.png'); background-size: cover;"></div>
                                        <div style="float: left; font-size: 7px; font-weight: 800">COMPRE & GANHE <span style="color: #5EB1D9">0 PONTOS</span></div>
                                    </div>
                                    <p align="center" style="font-family: Arial; font-weight: 900; color: black; font-size: 12px; padding-top: 15px;">Comprar com desconto</p>
                                </div>
                                <p id="cphConteudo_pDescontoPorcentagemDermaclub" align="center" style="color: white; font-weight: bold; font-size: 25px;"></p>
                            </div>-->

                            

                        </div>

                         
                        <div id="cphConteudo_divBuyArea" class="col4 buy-area">
                            <div id="cphConteudo_divDropQuantidade"><span class="group-title">Selecione a
                                <span id="cphConteudo_lblDescEspeci">Quantidade</span>:</span>
                                <div class="sku-radio"><span class="group-name">
                                    <span id="cphConteudo_lblDescEspeci1">Quantidade</span></span>
                                    <div class="sku-list">
                                        <ul>
                                            
                                                    <li class="sku-item"><a href="/actos-30mg-com-15-comprimidos/625/05" id="Urlfilhos"> 
                                                        <label class="sku-name" for="beach"> 
                                                            <img id="cphConteudo_rptProdutoFilhos_imgEspe_0" Border="0" src="https://www.onofre.com.br/estatico/produto/especificacao/382.jpg" height="40" width="40" />
                                                            <span>15 comprimidos</span> </label>
                                                    </a></li>
                                                
                                        </ul>
                                    </div>
                                </div>
                            </div>
                            
                            <div id="cphConteudo_main_product" class="main-product-price"><span>
                                <label></label>
                            </span><span id="cphConteudo_old_price_span" class="old-price"><em>
                                <span id="cphConteudo_lblPrecoDe">R$ 49,26</span></em></span>  <span class="regular-price">
                                    <span id="cphConteudo_lblPrecoPor">R$ 38,42</span></span> </div>
                            <div id="cphConteudo_divComprar" class="buy-product buy-page">
                                <div id="cphConteudo_botao_quantidade_antigo" class="qtd">
                                    <div class="controls"><span onclick="incrementValue()">+</span> <span onclick="DecrementValue()">-</span> </div>
                                    <input name="ctl00$cphConteudo$txt_QtdDP" type="text" id="txt_QtdDP" value="1" class="qtd-field" readonly="readonly" />
                                </div>
                                <a href="javascript:chamarAjaxQtd('AddItem','[{idProduct:625}]',parent.document.getElementById('txt_QtdDP').value);" id="cphConteudo_btComprarDP" class="btn-green btn-buy" onclick="SalvarCRMProduto">Comprar</a> </div>

                               <!--Quando o produto for derma club vai mostra um banner
                                <div style="top: 49%;left: 50%;margin-left: -25px;margin-top: 4px">
                                 <br />
                                         
                                 <a href="/loginloreal.aspx">
                                   <img id="derma-detalhe" style="display:none"   class="img-responsive" alt="derma club" src="../../img/DetalheProduto/dermaclub-detalhe.png"/>
                                  </a>
                                </div>  
                            -->
                               <!--*******************************************************************************-->


                            
                            
                            
                        </div>
                        <div>



 
                            
                        </div>
                        
                        

                        

                    </div>
                </div>
            </div>
            <div class="complementary row">
                
                <div id="AnvisaEtiquetaTextoSemBorda" class="AnvisaEtiquetaTextoSemBorda">
                    
                    
                </div>







                   </div>
            <div class="ch_clear" chaordic="top"></div>
            <div class="product-details tabs row col12">
                <nav class="tab-nav">
                    
                    <h2 id="cphConteudo_divDescricao_tab" class="tab-item active" data-item="descricao">Descrição do Produto</h2>
                    
                    <h2 id="cphConteudo_divGenerico_tab" class="tab-item" data-item="generico">Genérico</h2>
                </nav>
                
                <div id="cphConteudo_divDescricao" class="tab-content descricao active">
                    <p>
                        <style>
<!--
		@page { margin-left: 2cm; margin-right: 2cm; margin-top: 1.5cm; margin-bottom: 1.5cm }
		P { margin-bottom: 0cm; color: #000000; font-family: "Times New Roman", serif; font-size: 12pt; widows: 2; orphans: 2 }
		H1 { margin-top: 0cm; margin-bottom: 0cm; font-family: "Times New Roman", serif; font-size: 12pt; widows: 2; orphans: 2 }
		H2 { margin-left: 0.75cm; text-indent: 0.5cm; margin-top: 0cm; margin-bottom: 0cm; font-family: "Times New Roman", serif; font-size: 12pt; text-align: justify; widows: 2; orphans: 2 }
		H6 { margin-top: 0cm; margin-bottom: 0cm; font-family: "Times New Roman", serif; font-size: 12pt; text-align: justify; widows: 2; orphans: 2 }
	-->
</style>


<p align="left"><font color="#000000" face="Arial" size="2"><strong>ACTOS</strong></font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Pioglitazona,
cloridrato</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Identificação
do Produto</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Nome
do produto</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">ACTOS</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Nome
genérico (DCB)</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Cloridrato
de pioglitazona</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Formas
farmacêuticas e apresentações</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Comprimidos
de 15 mg: frascos com 15 comprimidos - Lista n° M859.</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Comprimidos
de 30 mg: frascos com 15 comprimidos - Lista n° M860.</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Comprimidos
de 45 mg: frascos com 15 comprimidos - Lista n° M861.</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">USO
ADULTO </font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Composição</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Cada
comprimido contém:</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Pioglitazona
(na forma de
cloridrato)................................................................................15
mg, 30 mg ou 45 mg</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Excipientes*
q.s.p.
...........................................................................................................................1
comprimido </font></p>

<p align="left"><font color="#000000" face="Arial" size="2">*Lactose
monoidratada, hidroxipropilcelulose, carboximetilcelulose
cálcica e estearato de magnésio.</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">INFORMAÇÃO
AO PACIENTE</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">ACTOS
(cloridrato de pioglitazona) é um antidiabético oral utilizado
como um coadjuvante de dieta e exercícios, para melhorar o
controle glicêmico em pacientes com diabetes melito tipo 2
(também conhecido como diabetes melito não insulino-dependente
ou de início da vida adulta). ACTOS (cloridrato de pioglitazona)
deve ser armazenado a temperatura ambiente, entre 15ºC e 30ºC.
Os frascos devem ser mantidos bem fechados e protegidos de
umidade. O prazo de validade está indicado na embalagem do
produto. Não use medicamento com o prazo de validade vencido,
poder ser perigoso para sua saúde. Não existem estudos
adequados e bem controlados em mulheres grávidas. ACTOS
(cloridrato de pioglitazona) deverá ser usado durante a gravidez
somente sob orientação médica. ACTOS (cloridrato de
pioglitazona) não deve ser administrado a mulheres durante o
período de amamentação. Informe ao médico se você estiver
grávida antes do tratamento e se engravidar ou desejar
engravidar durante o tratamento. Informe ao médico se estiver
amamentando. ACTOS (cloridrato de pioglitazona) deve ser tomado
uma vez ao dia independentemente da alimentação. O controle da
terapia antidiabética deve ser individualizada. Siga a
orientação do seu médico, respeitando sempre os horários, as
doses e a duração do tratamento. Não interromper o tratamento
sem o conhecimento de seu médico. Se durante o tratamento você
sentir efeitos desagradáveis como náuseas, vômitos, dor
abdominal, fadiga, falta de apetite, urina escura, ou qualquer
outro, deve informar isso ao médico. Os efeitos adversos mais
comuns são: infecção no trato respiratório superior, dor de
cabeça, sinusite, dores musculares, problemas dentários,
agravamento do diabetes melito e faringite. ACTOS (cloridrato de
pioglitazona) não deve ser utilizado em pacientes portadores de
diabetes tipo 1 ou para o tratamento de cetoacidose diabética.
ACTOS (cloridrato de pioglitazona) não é recomendado em
pacientes com menos de 18 anos de idade. Em mulheres na
pré-menopausa, pode ser necessário adotar precauções para
evitar uma gravidez. Mulheres em tratamento com ACTOS (cloridrato
de pioglitazona) que utilizam anticoncepcionais orais devem
adotar precauções adicionais para evitar uma gravidez. Informe
ao médico se estiver utilizando anticoncepcionais orais. Informe
ao médico se estiver usando medicamentos com cetoconazol ou
qualquer outro medicamento que esteja usando, antes do início,
ou durante o tratamento. Informe ao médico se você tem alguma
doença, especialmente no coração e no fígado. ACTOS
(cloridrato de pioglitazona) não está indicado em pacientes com
certos problemas cardíacos, pacientes com problemas no fígado
ou pacientes que fizeram uso de troglitazona e que apresentaram
icterícia ou qualquer doença do fígado durante o uso de
troglitazona. Para pacientes que estão mudando de troglitazona
para ACTOS (cloridrato de pioglitazona), recomenda-se um período
de uma semana sem utilizar a troglitazona antes de iniciar o
tratamento com ACTOS (cloridrato de pioglitazona).</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">TODO
MEDICAMENTO DEVE SER MANTIDO FORA DO ALCANCE DAS CRIANÇAS</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">NÃO
TOME REMÉDIO SEM O CONHECIMENTO DO SEU MÉDICO, PODE SER
PERIGOSO PARA A SAÚDE</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">INFORMAÇÃO
TÉCNICA</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Características</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">ACTOS
(cloridrato de pioglitazona) é um antidiabético oral que atua
principalmente reduzindo a resistência à insulina. ACTOS
(cloridrato de pioglitazona) é utilizado no manejo do diabetes
melito tipo 2 (também conhecido como diabetes melito não
insulino-dependente ou de início da vida adulta). Estudos
farmacológicos indicam que ACTOS (cloridrato de pioglitazona)
melhora a sensibilidade à insulina no músculo e tecido adiposo
e inibe a gliconeogênese hepática. ACTOS (cloridrato de
pioglitazona) melhora o controle glicêmico, uma vez que reduz os
níveis de insulina circulante. O cloridrato de pioglitazona
(cloridrato de (±)-5-[[4-[2-(5-etil-2piridinil) etoxi]
fenil]metil]-2,4-tiazolidinediona) pertence a uma classe química
diferente das sulfoniluréias, metformina ou dos inibidores da
alfa-glicosidase e possui uma ação farmacológica diferente. A
molécula contém um carbono assimétrico e o composto é
sintetizado e utilizado na forma da mistura racêmica. Os dois
enantiômeros da pioglitazona se interconvertem in vivo. Não
foram encontradas diferenças na atividade farmacológica entre
os dois enantiômeros. O cloridrato de pioglitazona é um pó
cristalino que possui fórmula molecular C<sub>19</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>S.HCl
e peso molecular igual a 392,90. É solúvel em
N,N-dimetilformamida, pouco solúvel em etanol anidro, muito
pouco solúvel em acetona e acetonitrila, praticamente insolúvel
em água e insolúvel em éter.</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Farmacologia
clínica</font></p>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Mecanismo de ação: ACTOS (cloridrato de
        pioglitazona) é um antidiabético da classe das
        tiazolidinedionas que depende da presença de insulina
        para seu mecanismo de ação. ACTOS (cloridrato de
        pioglitazona) diminui a resistência à insulina na
        periferia e no fígado, resultando em disposição
        aumentada de glicose dependente de insulina e produção
        diminuída de glicose hepática. Diferentemente das
        sulfoniluréias, a pioglitazona não é um secretagogo de
        insulina. A pioglitazona é um agonista potente e
        altamente seletivo dos receptores nucleares PPARgama
        (receptor gama proliferador de peroxisoma), que são
        encontrados em tecidos importantes para a ação da
        insulina, como o tecido adiposo, músculo esquelético e
        no fígado. A ativação dos receptores nucleares
        PPARgama modula a transcrição de um número de genes
        que respondem à insulina envolvidos no controle da
        glicose e do metabolismo lipídico. Em modelos animais de
        diabetes, a pioglitazona reduz a hiperglicemia, a
        hiperinsulinemia e a hipertrigliceridemia,
        características de estados resistentes à insulina como
        é o diabetes tipo 2. As alterações metabólicas
        produzidas pela pioglitazona resultam em resposta
        aumentada dos tecidos dependentes de insulina e são
        observadas em numerosos modelos animais de resistência
        à insulina. Uma vez que a pioglitazona aumenta os
        efeitos da insulina circulante (pela diminuição da
        resistência à insulina), não diminui a glicose
        sanguínea em modelos animais onde há falta de insulina
        endógena.</font></p>
    </li>
</ul>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Farmacodinâmica: Estudos clínicos
        demonstraram que ACTOS (cloridrato de pioglitazona)
        melhora a sensibilidade à insulina em pacientes com
        resistência a esta. ACTOS (cloridrato de pioglitazona)
        aumenta a resposta celular à insulina, aumenta a oferta
        de glicose dependente de insulina, melhora a
        sensibilidade hepática à insulina e melhora a
        homeostase disfuncional da glicose. Em pacientes com
        diabetes tipo 2, a diminuição da resistência à
        insulina, produzida por ACTOS (cloridrato de
        pioglitazona), resulta em concentrações mais baixas de
        glicose no sangue, níveis de insulina mais baixos no
        plasma e valores diminuídos de hemoglobina A1c (HbA1c).
        Com base nos resultados de um estudo, os efeitos
        hipoglicemiantes de ACTOS (cloridrato de pioglitazona)
        parecem persistir por pelo menos um ano. Em estudos
        clínicos controlados, ACTOS (cloridrato de pioglitazona)
        em combinação com sulfoniluréias, metformina ou
        insulina teve um efeito aditivo no controle glicêmico.
        Foram incluídos em estudos clínicos com ACTOS
        (cloridrato de pioglitazona) pacientes com disfunções
        lipídicas. No total, os pacientes tratados com ACTOS
        (cloridrato de pioglitazona) tiveram diminuição média
        dos triglicerídeos, aumento médio do colesterol-HDL e
        nenhuma alteração consistente no colesterol-LDL e
        total. Em um estudo controlado com placebo, de 26
        semanas, com doses escalonadas, os níveis médios de
        triglicerídeos diminuíram nos grupos recebendo 15 mg,
        30 mg e 45 mg de ACTOS (cloridrato de pioglitazona) em
        comparação a um aumento médio no grupo placebo. Os
        níveis médios de HDL aumentaram em maior extensão nos
        pacientes tratados com ACTOS (cloridrato de pioglitazona)
        do que nos pacientes tratados com placebo. Não houve
        diferenças consistentes no LDL e colesterol total nos
        pacientes tratados com ACTOS (cloridrato de pioglitazona)
        em relação aos pacientes tratados com placebo. Em
        outros dois estudos de monoterapia (24 semanas e 16
        semanas) e em estudos de terapia em combinação com
        sulfoniluréias (16 semanas) e metformina (16 semanas),
        os resultados foram consistentes com os dados anteriores.
        Em todos os estudos clínicos, uma redução na HbA1c foi
        acompanhada por um aumento no peso corpóreo nos
        pacientes tratados com ACTOS (cloridrato de pioglitazona)
        de forma relacionada à dose. Em estudos de monoterapia
        controlados com placebo, a alteração no peso médio
        para os pacientes tratados com ACTOS (cloridrato de
        pioglitazona) variou de 0,5 kg a 2,8 kg e para os
        pacientes tratados com placebo variou de 1,3 kg a 1,9 kg.
        Em combinação com sulfoniluréia, a alteração no peso
        médio foi de 1,9 kg e 2,9 kg para os pacientes recebendo
        15 mg e 30 mg de ACTOS (cloridrato de pioglitazona),
        respectivamente, e 0,8 kg para o placebo. Em combinação
        com insulina, a alteração no peso médio foi de 2,3 kg
        e 3,7 kg para os pacientes recebendo 15 mg e 30 mg de
        ACTOS (cloridrato de pioglitazona), respectivamente, e 0
        kg para o placebo. Em combinação com metformina, a
        alteração no peso médio foi de 1,0 kg para os
        pacientes recebendo 30 mg de ACTOS (cloridrato de
        pioglitazona) e 1,4 kg para o placebo.</font></p>
    </li>
</ul>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Farmacocinética e metabolismo: As
        concentrações séricas de pioglitazona total
        (pioglitazona e metabólitos ativos) permanecem elevadas
        24 horas após uma dose diária. Concentrações séricas
        da pioglitazona e da pioglitazona total em estado de
        equilíbrio são encontradas após 7 dias. Em estado de
        equilíbrio, dois dos metabólitos farmacologicamente
        ativos da pioglitazona, metabólitos III (M-III) e IV
        (M-IV), alcançam concentrações séricas iguais ou
        maiores do que a da pioglitazona. Tanto em voluntários
        saudáveis como em pacientes com diabetes tipo 2, a
        pioglitazona compreende aproximadamente 30% a 50% do pico
        da concentração sérica da pioglitazona total e 20% a
        25% da área total sob a curva de concentração sérica
        vs. tempo (AUC). A concentração sérica máxima (Cmáx)
        , AUC e a concentração sérica mínima (Cmin) para a
        pioglitazona e pioglitazona total aumentam
        proporcionalmente nas doses de 15 mg e 30 mg por dia. Há
        um aumento um pouco menos proporcional para a
        pioglitazona e pioglitazona total na dose de 60 mg por
        dia.</font></p>
    </li>
</ul>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Absorção: Após administração oral, em
        jejum, a pioglitazona é inicialmente mensurável no soro
        após 30 minutos, com pico de concentração observado
        após 2 horas. Alimentação retarda ligeiramente o tempo
        do pico da concentração sérica para 3 a 4 horas, mas
        não altera a extensão da absorção.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Distribuição: O volume aparente de
        distribuição médio da pioglitazona após
        administração de uma única dose é de 0,63 ± 0,41
        l/kg de peso corpóreo (média ± desvio padrão). A
        pioglitazona se liga extensamente às proteínas do soro
        humano (&gt;99%), principalmente à albumina sérica e
        com menor afinidade a outras proteínas. Os metabólitos
        M-III e M-IV também se ligam extensamente à albumina
        sérica (&gt;98%).</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Metabolismo: A pioglitazona é extensamente
        metabolizada por hidroxilação e oxidação. Os
        metabólitos também se convertem parcialmente em
        glicuronídeos ou conjugados sulfatados. Os metabólitos
        M-II e M-IV (hidroxiderivados da pioglitazona) e M-III
        (cetoderivado da pioglitazona) são farmacologicamente
        ativos em modelos animais de diabetes tipo 2. Em adição
        à pioglitazona, os metabólitos M-III e M-IV são os
        principais derivados da droga encontradas no soro humano
        após múltiplas doses. Em estado de equilíbrio, tanto
        em voluntários saudáveis como em pacientes com diabetes
        tipo 2, a pioglitazona compreende aproximadamente 30% a
        50% do pico total da concentração sérica e 20% a 25%
        da AUC total. A pioglitazona incubada com citocromo P-450
        humano ou microssomas de fígado humano resulta na
        formação de M-IV e, em grau muito menor, de M-II. As
        principais isoformas do citocromo P-450 envolvidas no
        metabolismo hepático da pioglitazona são a CYP2C8 e
        CYP3A4, com contribuições de uma variedade de outras
        isoformas, incluindo principalmente a extra hepática
        CYP1A1. Cetoconazol inibiu até 85% do metabolismo
        hepático da pioglitazona in vitro a uma concentração
        equimolar à da pioglitazona. A pioglitazona não inibiu
        a atividade do citocromo P-450 quando incubada com P-450
        de microssomas do fígado humano. Estudos in vivo em
        humanos não foram realizados para investigar qualquer
        indução da CYP3A4 pela pioglitazona.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Excreção e eliminação: Após
        administração oral, de 15% a 30% da dose de
        pioglitazona é recuperada na urina. A eliminação renal
        da pioglitazona é insignificante e a droga é
        principalmente excretada na forma de metabólitos e seus
        conjugados. Presume-se que a maior parte da dose oral
        seja excretada na bile, na forma inalterada ou na forma
        de metabólitos, e eliminada nas fezes. A meia-vida
        sérica média da pioglitazona e da pioglitazona total
        varia de 3 a 7 horas e de 16 a 24 horas, respectivamente.
        A pioglitazona tem uma depuração aparente calculada em
        5 a 7 l/h.</font></p>
    </li>
</ul>

<ul>
    <li><p style="text-indent: 0cm;" align="left"><font color="#000000" face="Arial" size="2">Populações
        especiais</font></p>
    </li>
</ul>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Insuficiência renal: A meia-vida de
        eliminação da pioglitazona, M-III e M-IV permanece
        inalterada em pacientes com disfunção renal moderada
        (depuração de creatinina = 30 a 60 ml/min) a severa
        (depuração de creatinina &lt;30 ml/min) quando
        comparada a indivíduos normais. Nenhum ajuste de dose é
        recomendado em pacientes com disfunção renal (ver
        Posologia).</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Insuficiência hepática: Comparados com
        controles normais, indivíduos com disfunção hepática
        (Child-Pugh grau B/C) têm uma redução de
        aproximadamente 45% na concentração média do pico da
        pioglitazona e da pioglitazona total, mas sem alteração
        dos valores de AUC médios. Terapia com ACTOS (cloridrato
        de pioglitazona) não deve ser iniciada se o paciente
        apresenta evidências clínicas de doença hepática
        ativa ou níveis de transaminase sérica acima de 2,5
        vezes o limite superior da normalidade (ver Precauções
        e advertências).</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Idosos: Em indivíduos idosos saudáveis, os
        picos de concentrações séricas de pioglitazona e
        pioglitazona total não são significativamente
        diferentes, mas os valores de AUC são ligeiramente
        maiores e os valores de meia-vida terminal se prolongam
        ligeiramente em relação a indivíduos mais jovens.
        Estas alterações não foram de uma magnitude que
        poderia ser considerada clinicamente relevante.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Crianças: Não há dados de
        farmacocinética disponíveis em população pediátrica.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Sexo: Os valores médios de Cmáx e AUC
        estavam aumentados de 20% a 60% no sexo feminino. Como
        monoterapia e em combinação com sulfoniluréias,
        metformina ou insulina, ACTOS (cloridrato de
        pioglitazona) melhora o controle glicêmico no sexo
        masculino e feminino. Em estudos clínicos controlados, a
        HbA1c diminui para valores basais, geralmente maior para
        o sexo feminino do que para o masculino (diferença
        média na HbA1c de 0,5%). Uma vez que a terapia deve ser
        individualizada para cada paciente para alcançar o
        controle glicêmico, não se recomenda ajuste de dose
        baseado somente no sexo.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Etnia: Não há dados de farmacocinética
        disponíveis para os vários grupos étnicos.</font></p>
    </li>
</ul>

<p style="margin-left: 0.75cm;" align="left"><font color="#000000" face="Arial" size="2">Indicações</font></p>

<p style="margin-left: 0.75cm;" align="left"><font color="#000000" face="Arial" size="2">ACTOS (cloridrato de pioglitazona) está
indicado como um coadjuvante de dieta e exercícios para melhorar
o controle glicêmico em pacientes com diabetes tipo 2 (diabetes
melito não insulino-dependente, DMNID). ACTOS (cloridrato de
pioglitazona) está indicado para monoterapia. ACTOS (cloridrato
de pioglitazona) está também indicado para uso em combinação
com sulfoniluréia, metformina, ou insulina, quando dieta e
exercício associados a um agente único não resultam em
controle adequado da glicemia. O acompanhamento de diabetes tipo
2 deverá também incluir aconselhamento nutricional, redução
de peso quando necessário e exercícios. Estas medidas são
importantes não só para tratamento primário, mas também para
manter a eficácia da terapia medicamentosa.</font></p>

<p style="margin-left: 0.75cm;" align="left"><font color="#000000" face="Arial" size="2">Contra-indicações</font></p>

<p style="margin-left: 0.75cm;" align="left"><font color="#000000" face="Arial" size="2">ACTOS (cloridrato de pioglitazona) é
contra-indicado em pacientes com conhecida hipersensibilidade a
pioglitazona ou a qualquer um de seus excipientes. </font></p>

<p style="margin-left: 0.75cm;" align="left"><font color="#000000" face="Arial" size="2">Precauções e advertências</font></p>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Geral: O cloridrato de pioglitazona exerce
        seu efeito anti-hiperglicêmico somente na presença de
        insulina. Portanto não deve ser utilizada em pacientes
        portadores de diabetes tipo 1 ou para o tratamento de
        cetoacidose diabética.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Hipoglicemia: Pacientes que estejam
        recebendo cloridrato de pioglitazona em combinação com
        insulina ou agentes hipoglicemiantes orais correm risco
        de apresentar hipoglicemia, podendo ser necessária a
        redução do agente concomitante.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Ovulação: Pacientes que estejam em
        período anovulatório pré-menopausa com resistência à
        insulina, o tratamento com tiazolidinedionas, incluindo
        pioglitazona, pode resultar em reinício da ovulação.
        Como conseqüência da sensibilidade aumentada à
        insulina, estas pacientes podem apresentar o risco de
        gravidez se contracepção adequada não for usada.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Hematológicas: A pioglitazona pode causar
        decréscimos na hemoglobina e hematócrito. Através de
        estudos clínicos, valores médios de hemoglobina
        declinaram de 2% a 4% nos pacientes tratados com
        cloridrato de pioglitazona. Estas alterações ocorreram
        primariamente dentro das primeiras 4 a 12 semanas de
        tratamento e permaneceram relativamente constantes. Estas
        alterações podem estar relacionadas com o aumento de
        volume plasmático e não foram associadas com nenhum
        efeito hematológico clinicamente significante (ver
        Reações adversas, Anormalidades laboratoriais).</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Edema: Pioglitazona deve ser usada com
        cuidado em pacientes com edema. Em estudos clínicos
        duplo-cegos de pacientes com diabetes tipo 2 foram
        registrados edemas leves a moderados em pacientes
        tratados com cloridrato de pioglitazona (ver Reações
        adversas).</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Cardíacas: Em estudos pré-clínicos,
        tiazolidinedionas, incluindo pioglitazona, causam
        expansão de volume plasmático e hipertrofia cardíaca
        induzida pela pré-carga (ver Precauções e
        advertências, Toxicologia animal). Em um estudo de 6
        meses, controlado com placebo, envolvendo 334 pacientes
        com diabetes tipo 2 e em um estudo aberto de longa
        duração (1 ano ou mais) envolvendo mais de 350
        pacientes com diabetes tipo 2, a avaliação
        ecocardiográfica não revelou aumento significante no
        índice médio de massa ventricular esquerda ou
        diminuição significante no índice cardíaco médio em
        pacientes tratados com cloridrato de pioglitazona. Em
        estudos clínicos que excluíram pacientes com condição
        cardíaca Classe III e IV da New York Heart Association
        (NYHA) não foi observado o aumento da incidência de
        eventos adversos cardíacos, potencialmente relacionados
        com expansão de volume. Pacientes com classe III e IV da
        NYHA não foram incluídos nos estudos clínicos com
        pioglitazona. A pioglitazona não está indicada em
        pacientes com condição cardíaca classe III ou IV da
        NYHA.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Efeitos hepáticos: Um outro fármaco da
        classe das tiazolidineodionas, troglitazona, foi
        associado com hepatotoxicidade idiossincrática, e casos
        muito raros de insuficiência hepática, transplantes de
        fígado e morte foram registrados durante o uso
        pós-comercialização. Em estudos clínicos controlados,
        pré-comercialização, em pacientes com diabetes tipo 2,
        a troglitazona foi mais freqüentemente associada com
        elevações significativas de enzimas hepáticas (TGP
        &gt; 3 vezes o limite superior de normalidade) comparada
        com placebo, e casos muito raros de icterícia
        reversível foram registrados. Em estudos clínicos em
        todo o mundo, mais de 4500 indivíduos foram tratados com
        cloridrato de pioglitazona. Em estudos clínicos nos
        Estados Unidos, mais de 2500 pacientes com diabetes tipo
        2 receberam cloridrato de pioglitazona. Não houve
        nenhuma evidência de hepatotoxicidade induzida pelo
        fármaco ou elevação dos níveis de TGP. Durante
        estudos clínicos controlados com placebo nos EUA, um
        total de 4 de 1526 (0,26%) dos pacientes tratados com
        cloridrato de pioglitazona e 2 de 793 (0,25%) dos
        pacientes tratados com placebo tiveram valores de TGP
        maior ou igual a 3 vezes o limite superior da
        normalidade. As elevações de TGP em pacientes tratados
        com cloridrato de pioglitazona foram reversíveis e não
        foram relacionadas com a terapia com pioglitazona. Embora
        os dados clínicos disponíveis não mostrem nenhuma
        evidência de hepatotoxicidade ou elevações de TGP
        induzidas por pioglitazona, a mesma está estruturalmente
        relacionada com a troglitazona, a qual tem sido associada
        com hepatoxicidade idiossincrática e raros casos de
        insuficiência hepática, transplantes de fígado e
        morte. Até que dados adicionais mais amplos sobre
        segurança da pioglitazona, provenientes de estudos
        clínicos controlados de longa duração e de
        farmacovigilância pós comercialização estejam
        disponíveis, recomenda-se que pacientes tratados com
        cloridrato de pioglitazona sejam submetidos a
        monitorações periódicas de enzimas hepáticas. Os
        níveis de TGP devem ser avaliados antes do início da
        terapia com cloridrato de pioglitazona em todos os
        pacientes, a cada 2 meses durante o primeiro ano de
        terapia e periodicamente após isto. Testes de função
        hepática também devem ser realizados se aparecerem
        sintomas sugestivos de disfunção hepática (náuseas,
        vômitos, dor abdominal, fadiga, anorexia, urina escura).
        A decisão de se continuar a terapia com cloridrato de
        pioglitazona deve ser guiada pelo julgamento clínico
        dependendo das avaliações laboratoriais. A terapia com
        cloridrato de pioglitazona não deve ser iniciada se o
        paciente exibir evidência clínica de doença hepática
        ativa ou níveis de TGP 2,5 vezes acima dos limites da
        normalidade. Pacientes com enzimas hepáticas
        moderadamente elevadas (níveis de TGP entre 1 e 2,5
        vezes acima do limite da normalidade), no momento basal
        ou a qualquer tempo durante a terapia com cloridrato de
        pioglitazona, devem ser avaliados para se determinar a
        causa desta elevação. O início ou a continuidade da
        terapia com cloridrato de pioglitazona em pacientes com
        elevação moderada de enzimas hepáticas deve ser
        procedida com cautela e deve incluir um seguimento
        clínico apropriado, o qual pode incluir uma
        monitoração mais frequente de enzimas hepáticas. Se os
        níveis de TGP estiverem 2,5 vezes acima dos limites da
        normalidade, testes de função hepática devem ser
        realizados com mais frequência até que seus níveis
        retornem ao normal ou a valores do pré-tratamento. Se os
        níveis de TGP permanecerem 3 vezes acima do normal ou se
        o paciente estiver ictérico, a terapia com cloridrato de
        pioglitazona deve ser descontinuada. Não existem dados
        disponíveis para se avaliar a segurança da pioglitazona
        em pacientes que apresentaram anormalidades hepáticas,
        disfunção hepática ou icterícia durante o uso de
        troglitazona. A pioglitazona não deve ser usada em
        pacientes que apresentaram icterícia durante o uso de
        troglitazona. Para pacientes com enzimas hepáticas
        normais que estão mudando de troglitazona para
        pioglitazona, recomenda-se um período de uma semana sem
        utilizar troglitazona antes de iniciar a pioglitazona.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Laboratório: Medidas de glicemia de jejum e
        hemoglobina glicosilada devem ser realizadas
        periodicamente para monitorar o controle glicêmico e a
        resposta terapêutica com cloridrato de pioglitazona, bem
        com enzimas hepáticas (ver Precauções e advertências,
        Efeitos hepáticos e Reações adversas).</font></p>
    </li>
</ul>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Carcinogênese, mutagênese, prejuízo da
        fertilidade: Dois anos de estudo em carcinogenicidade
        foram conduzidos em ratos machos e fêmeas com doses
        orais de até 63 mg/kg (aproximadamente 14 vezes o valor
        da dose oral máxima de 45 mg/m<sup>2</sup>, recomendada
        para humanos). Tumores induzidos pelo fármaco não foram
        observados em nenhum órgão exceto na bexiga urinária.
        Neoplasmas de células transicionais, benignas e/ou
        malignas foram observadas em ratos machos para doses de 4
        mg/kg/dia ou mais (aproximadamente igual a dose oral
        máxima em mg/m<sup>2</sup>,<sup> </sup>recomendada para
        humanos). A relação desses achados em ratos para
        humanos não é clara. Dois anos de estudo em
        carcinogenicidade foram conduzidos em camundongos machos
        e fêmeas com doses orais de 100 mg/kg/dia
        (aproximadamente 11 vezes a dose oral máxima em mg/m<sup>2</sup>,<sup>
        </sup>recomendada para humanos). Tumores induzidos pelo
        fármaco não foram observados em nenhum órgão. Durante
        a avaliação prospectiva de citologia urinária,
        envolvendo mais de 1800 pacientes recebendo pioglitazona
        em estudos clínicos de até um ano de duração, nenhum
        caso novo de tumor de bexiga foi identificado.
        Ocasionalmente, resultados anormais de citologia
        urinária indicando possível malignidade foram
        observados tanto com pacientes tratados com cloridrato de
        pioglitazona (0,72%) como com placebo (0,88%).
        Pioglitazona não foi mutagênica em uma bateria de
        estudos de toxicologia genética, incluindo o teste
        bacteriano de Ames, um teste de ativação mutagênica de
        células de mamíferos (CHO, HPRT e AS52/XPRT), um teste
        citogenético in vitro usando células CHL, um teste de
        síntese de DNA não programado e um teste in vivo de
        micronúcleos. Nenhum evento adverso sobre fertilidade
        foi observado em ratos machos e fêmeas para doses orais
        de até 40 mg/kg/dia de cloridrato de pioglitazona antes
        e durante o acasalamento e gestação (aproximadamente 9
        vezes a dose oral máxima em mg/m<sup>2</sup>,
        recomendada para humanos). </font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Toxicologia animal: Foi observado aumento do
        coração em camundongos (100 mg/kg), em ratos
        (&gt;4mg/kg) e em cães (3 mg/kg) tratados oralmente com
        cloridrato de pioglitazona (aproximadamente 11, 1, e 2
        vezes a dose oral máxima em mg/m<sup>2</sup>,
        recomendada para humanos, respectivamente). Em um estudo
        de um ano em ratos, morte precoce relacionada com o
        fármaco, devido a aparente disfunção cardíaca,
        ocorreu na dose oral de 160 mg/kg/dia (35 vezes a dose
        oral máxima em mg/m<sup>2</sup>,<sup> </sup>recomendada
        para humanos). Aumento cardíaco foi observado em um
        estudo de 13 semanas em macacos, utilizando-se doses
        orais &gt; 8,9 mg/kg (4 vezes a dose oral máxima em mg/m<sup>2</sup>,
        recomendada para humanos), mas não foi visto em um
        estudo de 52 semanas utilizando-se doses orais até 32
        mg/kg (aproximadamente 13 vezes a dose oral máxima em
        mg/m<sup>2</sup>, recomendada para humanos).</font></p>
    </li>
</ul>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Gravidez: Pioglitazona não foi
        teratogênica em ratos para doses orais até 80 mg ou em
        coelhos recebendo até 160 mg/kg durante a organogênese
        (aproximadamente 17 e 40 vezes a dose oral máxima em
        mg/m<sup>2</sup>, recomendada para humanos). Parto
        demorado e embriotoxicidade foram observados em ratos
        para doses orais &gt; 40 mg/kg/dia (aproximadamente 10
        vezes a dose oral máxima em mg/m<sup>2</sup>,
        recomendada para humanos). Nenhuma toxicidade funcional
        ou comportamental foi observada na prole de ratos.
        Embriotoxicidade foi observada em coelhos para uma dose
        oral de 160 mg/kg (aproximadamente 40 vezes a dose oral
        máxima em mg/m<sup>2</sup>, recomendada para humanos).
        Atraso de desenvolvimento pós natal atribuído ao
        decréscimo de peso corporal foi observado na prole de
        ratos para doses orais &gt; 10 mg/kg durante os períodos
        de final da gestação e lactação (aproximadamente 2
        vezes a dose oral máxima em mg/m<sup>2</sup>,
        recomendada para humanos). Não existem estudos adequados
        e bem controlados em mulheres grávidas. Pioglitazona
        deverá ser usada durante a gravidez somente se os
        potenciais benefícios justificarem o risco potencial
        para o feto. Devido à atual informação sugerir
        fortemente que níveis anormais de glicose sanguínea
        durante a gestação estarem associados com alta
        incidência de anomalias congênitas, bem como com o
        aumento da morbidade e mortalidade neonatais, a maioria
        dos especialistas recomendam o uso da insulina durante a
        gestação para manter os níveis de glicose sanguínea o
        mais próximo possível da normalidade.</font></p>
    </li>
</ul>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Lactação: Pioglitazona é secretada no
        leite de ratas durante o período de lactação. Não se
        sabe se a pioglitazona é secretada no leite humano.
        Devido ao fato de muitos fármacos serem excretados no
        leite humano, a pioglitazona não deve ser administrada a
        mulheres durante o período de amamentação.</font></p>
    </li>
</ul>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Uso pediátrico: A segurança e eficácia da
        pioglitazona não foram estabelecidas em pacientes
        pediátricos.</font></p>
    </li>
</ul>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Uso em idosos: Aproximadamente 500 pacientes
        com 65 anos ou mais participaram de estudos clínicos de
        pioglitazona controlados com placebo. Nenhuma diferença
        significante na eficácia e segurança foi observada
        entre esses pacientes e outros mais jovens.</font></p>
    </li>
</ul>

<p align="left"><font color="#000000" face="Arial" size="2">Interações
medicamentosas</font></p>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Contraceptivos orais: A administração de
        outra tiazolidinediona com um contraceptivo oral contendo
        etinilestradiol e noretindrona, reduziu as
        concentrações plasmáticas de ambos os hormônios em
        aproximadamente 30%, o que poderia resultar em perda do
        efeito contraceptivo. A farmacocinética da
        co-administração de pioglitazona e contraceptivos orais
        não foi avaliada em pacientes, devendo ser adotadas
        precauções adicionais relativas à contracepção em
        pacientes que estejam recebendo pioglitazona.</font></p>
    </li>
</ul>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Glipizida: Em voluntários sadios, a
        co-administração de pioglitazona (45 mg uma vez ao dia)
        e glipizida (5 mg uma vez ao dia) por 7 dias não alterou
        o estado de equilíbrio farmacocinético da glipizida.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Digoxina: Em voluntários sadios, a
        co-administração de pioglitazona (45 mg uma vez ao dia)
        e digoxina ( 0,25 mg uma vez ao dia) por 7 dias não
        alterou o estado de equilíbrio farmacocinético da
        digoxina.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Varfarina: Em voluntários sadios, a
        co-administração de pioglitazona (45 mg uma vez ao dia)
        por 7 dias com varfarina, não alterou o estado de
        equilíbrio farmacocinético da varfarina.
        Adicionalmente, a pioglitazona não teve efeito
        clinicamente significante no tempo de protrombina quando
        administrada para pacientes em terapia crônica com
        varfarina.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Metformina: Em voluntários sadios, a
        co-administração de pioglitazona (45 mg uma vez ao dia)
        e metformina (1000 mg) após 7 dias de pioglitazona, não
        alterou a farmacocinética da dose única de metformina.</font></p>
    </li>
</ul>

<p align="left"><font color="#000000" face="Arial" size="2">A
isoforma do citocromo P450 CYP3A4 é parcialmente responsável
pelo metabolismo da pioglitazona. Não foram realizados estudos
específicos e formais de interação farmacocinética com
pioglitazona e outros fármacos metabolizados por esta enzima
tais como eritromicina, astemizol, bloqueadores de canais de
cálcio, cisaprida, corticosteróides, ciclosporina, inibidores
da HMG-CoA redutase, tacrolimus, trimetrexato, bem como fármacos
inibidores com cetoconazol e itraconazol. In vitro, o cetoconazol
parece inibir significantemente o metabolismo da pioglitazona
(ver Farmacologia clínica, Metabolismo). Dependendo da
disponibilidade de dados adicionais o controle glicêmico deverá
ser realizado com maior frequência nos pacientes que estejam
recebendo concomitantemente cetoconazol e pioglitazona.</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Reações
adversas</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Em
todo o mundo, acima de 3.700 pacientes com diabetes tipo 2,
participantes de estudos clínicos, têm sido tratados com
pioglitazona. Nos EUA, mais de 2.500 receberam pioglitazona em
estudos clínicos, mais de 1.100 foram tratados por seis meses ou
mais e mais de 450 pacientes foram tratados com pioglitazona por
um ano ou mais. A incidência geral e os tipos de eventos
adversos relatados em estudos clínicos controlados com placebo
utilizando a pioglitazona como monoterapia nas doses de 7,5 mg,
15 mg, 30 mg ou 45 mg uma vez ao dia são mostrados na tabela a
seguir:</font></p>
<div align="center"><center>

<p align="left"><font color="#000000" face="Arial" size="2"></font>&nbsp;</p>
    <p align="left"><font color="#000000" face="Arial" size="2"></font>&nbsp;</p>
    <table border="1" bordercolor="#000000" cellpadding="3" cellspacing="0" width="576">
    <tbody><tr>
        <td colspan="3" valign="top" width="568"><p align="left"><font color="#000000" face="Arial" size="2">Estudos clínicos
        de pioglitazona em monoterapia,</font></p>
        <p align="left"><font color="#000000" face="Arial" size="2">controlados com placebo: Eventos adversos</font></p>
        <p align="left"><font color="#000000" face="Arial" size="2">relatados com frequência &gt; 5% dos
        pacientes tratados</font></p>
        <p align="left"><font color="#000000" face="Arial" size="2">com pioglitazona.</font></p>
        </td>
    </tr>
    <tr>
        <td rowspan="2" valign="top" width="281"><p align="left"><font color="#000000" face="Arial" size="2">Evento adverso</font></p>
        </td>
        <td colspan="2" valign="top" width="281"><p align="left"><font color="#000000" face="Arial" size="2">% de pacientes</font></p>
        </td>
    </tr>
    <tr>
        <td valign="top" width="138"><p align="left"><font color="#000000" face="Arial" size="2">Placebo N = 259</font></p>
        </td>
        <td valign="top" width="137"><p align="left"><font color="#000000" face="Arial" size="2">Pioglitazona N =
        606</font></p>
        </td>
    </tr>
    <tr>
        <td valign="top" width="281"><p align="left"><font color="#000000" face="Arial" size="2">Infecção do trato
        respiratório superior</font></p>
        </td>
        <td valign="top" width="138"><p align="left"><font color="#000000" face="Arial" size="2">8,5</font></p>
        </td>
        <td valign="top" width="137"><p align="left"><font color="#000000" face="Arial" size="2">13,2</font></p>
        </td>
    </tr>
    <tr>
        <td valign="top" width="281"><p align="left"><font color="#000000" face="Arial" size="2">Cefaléia</font></p>
        </td>
        <td valign="top" width="138"><p align="left"><font color="#000000" face="Arial" size="2">6,9</font></p>
        </td>
        <td valign="top" width="137"><p align="left"><font color="#000000" face="Arial" size="2">9,1</font></p>
        </td>
    </tr>
    <tr>
        <td valign="top" width="281"><p align="left"><font color="#000000" face="Arial" size="2">Sinusite</font></p>
        </td>
        <td valign="top" width="138"><p align="left"><font color="#000000" face="Arial" size="2">4,6</font></p>
        </td>
        <td valign="top" width="137"><p align="left"><font color="#000000" face="Arial" size="2">6,3</font></p>
        </td>
    </tr>
    <tr>
        <td valign="top" width="281"><p align="left"><font color="#000000" face="Arial" size="2">Mialgia</font></p>
        </td>
        <td valign="top" width="138"><p align="left"><font color="#000000" face="Arial" size="2">2,7</font></p>
        </td>
        <td valign="top" width="137"><p align="left"><font color="#000000" face="Arial" size="2">5,4</font></p>
        </td>
    </tr>
    <tr>
        <td height="13" valign="top" width="281"><p align="left"><font color="#000000" face="Arial" size="2">Desordens
        dentárias</font></p>
        </td>
        <td valign="top" width="138"><p align="left"><font color="#000000" face="Arial" size="2">2,3</font></p>
        </td>
        <td valign="top" width="137"><p align="left"><font color="#000000" face="Arial" size="2">5,3</font></p>
        </td>
    </tr>
    <tr>
        <td valign="top" width="281"><p align="left"><font color="#000000" face="Arial" size="2">Diabetes melito
        agravado</font></p>
        </td>
        <td valign="top" width="138"><p align="left"><font color="#000000" face="Arial" size="2">8,1</font></p>
        </td>
        <td valign="top" width="137"><p align="left"><font color="#000000" face="Arial" size="2">5,1</font></p>
        </td>
    </tr>
    <tr>
        <td valign="top" width="281"><p align="left"><font color="#000000" face="Arial" size="2">Faringite</font></p>
        </td>
        <td valign="top" width="138"><p align="left"><font color="#000000" face="Arial" size="2">0,8</font></p>
        </td>
        <td valign="top" width="137"><p align="left"><font color="#000000" face="Arial" size="2">5,1</font></p>
        </td>
    </tr>
</tbody></table>
</center></div>

<p align="left"><font color="#000000" face="Arial" size="2">Os
eventos adversos clínicos quando a pioglitazona foi usada em
combinação com sulfoniluréias (n = 373), metformina (n = 168)
ou insulina (n = 379), foram geralmente similares aos relatados
durante a monoterapia com pioglitazona, exceto pelo aumento da
ocorrência de edema no estudo de combinação com insulina
(pioglitazona 15% e placebo 7%). A incidência de retiradas de
pacientes dos estudos clínicos, devido a um evento adverso
diferente de hiperglicemia, foi similar para pacientes tratados
com placebo (2,8%) ou com pioglitazona (3,3%). Hipoglicemia leve
a moderada foi relatada durante a terapia combinada com
sulfoniluréia ou insulina. Hipoglicemia foi registrada para 1%
dos pacientes tratados com placebo e em 2% dos pacientes tratados
com pioglitazona combinada com sulfoniluréia. Na combinação
com insulina, a hipoglicemia foi relatada para 5% dos pacientes
tratados com placebo, 8% para os tratados com 15 mg de cloridrato
de pioglitazona e 15% para os tratados com 30 mg de cloridrato de
pioglitazona (ver Precauções e advertências, Hipoglicemia).
Nos estudos duplo-cegos de monoterapia americanos, a anemia foi
registrada em 1% dos pacientes tratados com pioglitazona e 0% dos
tratados com placebo. Quando em combinação com insulina, a
anemia foi registrada em 1,6% tanto em pacientes tratados com
pioglitazona como com placebo. A anemia foi também registrada
nos estudos de combinação com sulfoniluréia em 0,3% dos
pacientes tratados com pioglitazona e 1,6% com placebo. Quando em
combinação com metformina as porcentagens foram de 1,2% e 0%
dos pacientes tratados respectivamente com pioglitazona e
placebo. Ainda nos estudos clínicos americanos, edema foi
registrado com mais frequência nos pacientes tratados com
pioglitazona do que com placebo. Em estudos de monoterapia, edema
foi registrado em 4,8% e 1,2% dos pacientes tratados com
pioglitazona e placebo, respectivamente. Na combinação com
insulina, o edema foi mais frequente nos pacientes tratados com
pioglitazona (15,3%) do que nos tratados com placebo (7,0%).
Todos eventos foram considerados de intensidade leve ou moderada
(ver Precauções e advertências, Edema).</font></p>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Anormalidades laboratoriais</font></p>
    </li>
</ul>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Hematológicas: A pioglitazona pode causar
        diminuição dos valores de hematócrito e hemoglobina.
        Durante todos os estudos clínicos, os valores médios de
        hemoglobina declinaram em torno de 2 a 4% nos pacientes
        tratados com pioglitazona. Estas alterações ocorreram
        dentro das primeiras 4 a 12 semanas de tratamento e
        permaneceram relativamente estáveis após este período
        e, podem estar relacionadas com o aumento do volume
        plasmático associado à terapia com pioglitazona e não
        têm sido associadas com nenhum efeito clínico
        hematológico significante.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Transaminase sérica: Durante estudos
        americanos controlados com placebo, 4 de 1526 (0,26%)
        pacientes tratados com pioglitazona e 2 de 793 (0,25%)
        pacientes tratados com placebo tiveram valores de TGP
        &gt; 3 vezes o limite da normalidade. Durante todos os
        estudos clínicos nos EUA, 11 de 2561 (0,43%) pacientes
        tratados com pioglitazona tiveram valores de TGO &gt; 3
        vezes os limites da normalidade. Todos os pacientes com
        valores de segmento tiveram elevações reversíveis de
        TGP. Na população de pacientes tratados com
        pioglitazona os valores médios de bilirrubina, TGO, TGP,
        fosfatase alcalina e gama GT estavam diminuídos na
        visita final quando comparados com os respectivos valores
        basais. Menos de 0,12% dos pacientes tratados com
        pioglitazona saíram dos estudos americanos devido a
        testes anormais de funções hepáticas. Em estudos
        clínicos pré-comercialização não existem casos de
        reações idiossincráticas pelo fármaco levando a
        insuficiência hepática.</font></p>
    </li>
</ul>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">CPK (creatinina fosfoquinase): Durante
        testes laboratoriais requeridos em estudos clínicos,
        foram observadas elevações esporádicas e transitórias
        nos níveis de CPK. Uma elevação única e isolada para
        níveis maiores que 10 vezes acima do limite da
        normalidade (valores de 2150 a 8610) foi notada em 7
        pacientes; 5 destes pacientes continuaram a receber
        pioglitazona e os outros 2 completaram o recebimento da
        medicação do estudo até o momento do resultado do
        valor elevado. Essas elevações resolveram-se sem
        qualquer sequela clínica aparente. A relação desses
        eventos e a terapia com pioglitazona é desconhecida.</font></p>
    </li>
</ul>

<p align="left"><font color="#000000" face="Arial" size="2">Posologia
e modo de usar</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">ACTOS
(cloridrato de pioglitazona) deve ser tomado uma vez ao dia
independentemente da alimentação. O controle da terapia
antidiabética deve ser individualizada. Idealmente, a resposta
ao tratamento deve ser avaliada usando-se a hemoglobina
glicosilada (HbA1c), que é um melhor indicador do controle
glicêmico a longo prazo quando comparado com glicemia de jejum
unicamente. HbA1c reflete a glicemia dos últimos 2 a 3 meses. No
uso clínico, recomenda-se que o paciente seja tratado com ACTOS
(cloridrato de pioglitazona) por um período de tempo adequado
para se avaliar as alterações de HbA1c (3 meses) a não ser que
o controle glicêmico se deteriore.</font></p>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Monoterapia: A monoterapia com ACTOS
        (cloridrato de pioglitazona) em pacientes sem controle
        adequado de dieta e exercícios pode ser iniciada com 15
        mg ou 30 mg uma vez ao dia. Para pacientes que respondem
        inadequadamente à dose inicial de ACTOS (cloridrato de
        pioglitazona), a dose pode ser aumentada em incrementos
        de até 45 mg uma vez ao dia. Em pacientes que não
        respondem adequadamente à monoterapia, uma terapia
        combinada pode ser considerada.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Terapia combinada:</font></p>
    </li>
</ul>

<ul>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Sulfoniluréia: ACTOS (cloridrato de
        pioglitazona), em combinação com uma sulfoniluréia,
        pode ser iniciado nas doses de 15 mg a 30 mg uma vez ao
        dia. A dose da sulfoniluréia em uso pode ser continuada
        na inicialização da terapia com ACTOS (cloridrato de
        pioglitazona). Se o paciente apresentar hipoglicemia, a
        dose da sulfoniluréia deverá ser diminuída.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Metformina: ACTOS (cloridrato de
        pioglitazona), em combinação com metformina, pode ser
        iniciado nas doses de 15 mg a 30 mg uma vez ao dia. A
        dose da metformina em uso pode ser continuada na
        inicialização da terapia com ACTOS (cloridrato de
        pioglitazona). É improvável que seja necessário ajuste
        na dose de metformina devido à hipoglicemia durante a
        combinação com ACTOS (cloridrato de pioglitazona).</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Insulina: ACTOS (cloridrato de pioglitazona)
        em combinação com insulina pode ser iniciado nas doses
        de 15 mg a 30 mg uma vez ao dia. Nos pacientes que
        estejam recebendo ACTOS (cloridrato de pioglitazona) e
        insulina, a dose de insulina pode ser diminuída em torno
        de 10 a 20% se o paciente apresentar hipoglicemia ou se
        as concentrações de glicose plasmática diminuírem
        para valores menores de 100 mg/dl. Maiores ajustes
        deverão ser individualizados, baseando-se na resposta de
        diminuição da glicose.</font></p>
    </li>
    <li><p align="left"><font color="#000000" face="Arial" size="2">Dose máxima recomendada: As doses de
        ACTOS(cloridrato de pioglitazona) não devem exceder a 45
        mg uma vez ao dia, pois doses maiores que 45 mg uma vez
        ao dia não foram estudadas em estudos clínicos
        controlados com placebo. Nenhum estudo clínico foi
        conduzido com doses maiores que 30 mg uma vez ao dia em
        terapia combinada. Não é recomendado o ajuste de doses
        em pacientes com insuficiência renal (ver Farmacologia
        clínica, Farmacocinética e metabolismo). O tratamento
        com ACTOS (cloridrato de pioglitazona) não deve ser
        iniciado se o paciente mostrar evidência clínica de
        doença hepática ativa ou aumento de níveis de
        transaminase sérica (TGP &gt; 2,5 vezes o limite da
        normalidade) no início do tratamento. Recomenda-se a
        monitoração de enzima hepática em todos os pacientes
        que estejam iniciando a terapia com ACTOS (cloridrato de
        pioglitazona) bem como periodicamente após o início
        (ver Precauções e advertências e Farmacologia
        clínica). Não existem dados sobre o uso de ACTOS
        (cloridrato de pioglitazona) em pacientes abaixo de 18
        anos de idade, portanto o uso de pioglitazona em
        pacientes pediátricos não é recomendado. Não há
        dados disponíveis sobre o uso de pioglitazona em
        combinação com outra tiazolidinediona.</font></p>
    </li>
</ul>

<p align="left"><font color="#000000" face="Arial" size="2">Superdosagem</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Durante
os estudos clínicos, um caso de superdosagem foi registrado. Um
paciente do sexo masculino tomou 120 mg/dia por 4 dias e após
isto 180 mg/dia por 7 dias. O paciente negou qualquer sintoma
clínico durante este período. Em caso de superdosagem, deve ser
iniciado tratamento de suporte adequado, de acordo com os
sintomas e sinais clínicos do paciente.</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Armazenamento</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">ACTOS
(cloridrato de pioglitazona) deve ser armazenado a temperatura
ambiente, entre 15º C e 30º C. Os frascos devem ser mantidos
bem fechados e protegidos de umidade.</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">ESTE
PRODUTO É UM NOVO MEDICAMENTO E EMBORA AS PESQUISAS TENHAM
INDICADO EFICÁCIA E SEGURANÇA, QUANDO CORRETAMENTE INDICADO,
PODEM OCORRER REAÇÕES ADVERSAS IMPREVISÍVEIS, AINDA NÃO
DESCRITAS OU CONHECIDAS. EM CASO DE SUSPEITA DE REAÇÃO ADVERSA,
O MÉDICO RESPONSÁVEL DEVE SER NOTIFICADO.</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">VENDA
SOB PRESCRIÇÃO MÉDICA </font></p>

<p style="line-height: 0.42cm;" align="left"><font color="#000000" face="Arial" size="2">SÓ PODE SER VENDIDO COM RETENÇÃO DE
RECEITA</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">MS
n° 1.0553.0238</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Resp.
Téc.: Farm. Renate Blohm</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">CRF-SP
nº 4176</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Fabricado
por: Takeda Chemical Industries, Ltd. - Osaka - Japão</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Distribuído
por: Abbott Laboratórios do Brasil Ltda.</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Rua
Nova York, 245</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">ATENDIMENTO</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">AO
CONSUMIDOR</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">CAIXA
POSTAL Nº 21.130</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">CEP:
04698-970</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">São
Paulo - SP </font></p>

<p align="left"><font color="#000000" face="Arial" size="2">C.N.P.J.
nº 56.998.701/0001-16</font></p>

<p align="left"><font color="#000000" face="Arial" size="2">Nº
de lote, data de fabricação e validade: vide rótulo e
cartucho.</font></p>
                    </p>
                </div>
                <div id="cphConteudo_divGenerico" class="tab-content generico" style="border-bottom: 0px">
                    <div id="cphConteudo_dvGenerico" class="generic col12">
                        <div class="shelf-generic column3">
                            <ul class="shelf-list-generic">
                                
                                        <li class="shelf-item-generic">
                                            <div class="shelf-generic-product" data-productid="123">
                                                <p class="product-name"><a href="#" title="">
                                                    <span id="cphConteudo_rptGenericos_lblDescriptionGeneric_0">Cloridrato de Pioglitazona 30mg Com 15 Comprimidos - EMS Genéricos</span>
                                                </a></p>
                                                <div class="product-price"><a href="#" title=""><span class="regular-price">
                                                    <span id="cphConteudo_rptGenericos_lblPricePerGeneric_0">R$ 19,99</span></span> <span class="economy">
                                                        <span id="cphConteudo_rptGenericos_lblPriceEconomic_0">Economize R$ 18,43</span></span> </a></div>
                                                <div class="buy-generic-product">
                                                    <input type="submit" name="ctl00$cphConteudo$rptGenericos$ctl00$imgBtnGeneric" value="COMPRAR" onclick="javascript:chamarAjaxQtd(&#39;AddItem&#39;,&#39;[{&quot;idProduct&quot;:54594}]&#39;,1);" id="cphConteudo_rptGenericos_imgBtnGeneric_0" class="btn-yellow buy-generic" alt="Comprar" />
                                                </div>
                                            </div>
                                        </li>
                                    
                                        <li class="shelf-item-generic">
                                            <div class="shelf-generic-product" data-productid="123">
                                                <p class="product-name"><a href="#" title="">
                                                    <span id="cphConteudo_rptGenericos_lblDescriptionGeneric_1">Cloridrato de Pioglitazona 30mg C/ 30 ComprimidosNova Química Genérico</span>
                                                </a></p>
                                                <div class="product-price"><a href="#" title=""><span class="regular-price">
                                                    <span id="cphConteudo_rptGenericos_lblPricePerGeneric_1">R$ 76,74</span></span> <span class="economy">
                                                        <span id="cphConteudo_rptGenericos_lblPriceEconomic_1"></span></span> </a></div>
                                                <div class="buy-generic-product">
                                                    <input type="submit" name="ctl00$cphConteudo$rptGenericos$ctl01$imgBtnGeneric" value="COMPRAR" onclick="javascript:chamarAjaxQtd(&#39;AddItem&#39;,&#39;[{&quot;idProduct&quot;:7972}]&#39;,1);" id="cphConteudo_rptGenericos_imgBtnGeneric_1" class="btn-yellow buy-generic" alt="Comprar" />
                                                </div>
                                            </div>
                                        </li>
                                    
                                        <li class="shelf-item-generic">
                                            <div class="shelf-generic-product" data-productid="123">
                                                <p class="product-name"><a href="#" title="">
                                                    <span id="cphConteudo_rptGenericos_lblDescriptionGeneric_2">Cloridrato de Pioglitazona 30mg 15 Comprimidos-Nova Química Genérico</span>
                                                </a></p>
                                                <div class="product-price"><a href="#" title=""><span class="regular-price">
                                                    <span id="cphConteudo_rptGenericos_lblPricePerGeneric_2">R$ 40,63</span></span> <span class="economy">
                                                        <span id="cphConteudo_rptGenericos_lblPriceEconomic_2"></span></span> </a></div>
                                                <div class="buy-generic-product">
                                                    <input type="submit" name="ctl00$cphConteudo$rptGenericos$ctl02$imgBtnGeneric" value="COMPRAR" onclick="javascript:chamarAjaxQtd(&#39;AddItem&#39;,&#39;[{&quot;idProduct&quot;:7971}]&#39;,1);" id="cphConteudo_rptGenericos_imgBtnGeneric_2" class="btn-yellow buy-generic" alt="Comprar" />
                                                </div>
                                            </div>
                                        </li>
                                    
                            </ul>
                        </div>
                    </div>
                </div>
                <div class="tab-content video">
                    <p>
                        
                    </p>
                </div>
            </div>
            <div class="ch_clear" chaordic="middle"></div>
            
            <div class="ch_clear" chaordic="bottom"></div>
        </div>
    </div>
    <div class="zx_48A4A1065492484E8D54 zx_mediaslot">
       <script type="text/javascript">
           /*<![CDATA[*/
           window._zx = window._zx || [];
           window._zx.push({
               id: "48A4A1065492484E8D54"
           });
           (function (e) {
               var c = e.createElement("script");
               c.async = true;
               c.src = (e.location.protocol == "https:" ? "https:" : "http:") + "//static.zanox.com/scripts/zanox.js?utm_source=Zanox&utm_medium=Afiliados&utm_campaign=Desconto&acao=3&partner=576";
               var b = e.getElementsByTagName("script")[0];
               b.parentNode.insertBefore(c, b)
           }(document)); /*]]>*/
        </script>
        <script type="text/javascript">
            var images = window.chaordic_meta.product.images;
            var zx_identifier = window.chaordic_meta.product.id;
            var zx_name = window.chaordic_meta.product.name;
            var zx_price = window.chaordic_meta.product.price;
            var zx_url = window.location.host + window.chaordic_meta.product.url;
            var zx_photo = window.location.host + images["300x300"];
        </script>
        <script type="text/javascript">
            var IP;
            /*<![CDATA[*/
            function incrementValue() {
                var a = parseInt(document.getElementById("txt_QtdDP").value, 10);
                a = isNaN(a) ? 0 : a;
                a++;
                if (a == 21) {
                    a = 20
                }
                //if (a < 10) {
                //    a = ("0" + a)
                //}

                document.getElementById("txt_QtdDP").value = a
            }

            function DecrementValue() {
                var a = parseInt(document.getElementById("txt_QtdDP").value, 10);
                a = isNaN(a) ? 0 : a;
                a--;
                if (a == 0) {
                    a = 1
                }
                //if (a < 10) {
                //    a = ("0" + a)
                //}
                document.getElementById("txt_QtdDP").value = a
            }
            $("#txt_QtdDP").on("keyup blur", function (a) {
                $(this).val($(this).val().replace(/[^\d].+/, ""));
                if ((a.which < 48 || a.which > 57)) {
                    a.preventDefault()
                }


            });

            //$("#txt_QtdDP").on("keyup blur", function () {
            //    if ($("#txt_QtdDP").val() > 50) {
            //        $("#txt_QtdDP").val("0" + 1)
            //    }
            //    if ($("#txt_QtdDP").val() == "") {
            //        $("#txt_QtdDP").val("0" + 1)
            //    }
            //}); /*]]>*/




            $.get("https://ipinfo.io", function (response) {
                IP = response.ip;
            }, "jsonp");


            $("#cphConteudo_btComprarDP").click(function () {

                SalvarCRMProduto();
            });


            function SalvarCRMProduto() {

                $.ajax({
                    type: "POST",
                    url: "/DetalheProduto/Default.aspx/SalvarCrm",
                    data: "{id_produto:'" + $("#cphConteudo_hf_id_produto").val() + "',UF:'" + $("#cphConteudo_slCrmUF").val() + "',CRM:'" + $("#cphConteudo_txtCrm").val() + "',IP:'" + IP + "'}",
                    contentType: "application/json; charset=utf-8",
                    dataType: "json",
                    success: function (data) {
                        //if (data.d == "Salvo") {


                        //} else if (data.d == "Não Salvo") {

                        //}

                    },
                    error: function (data) {

                    }
                });

            }

        </script>
    </div>
    <style type="text/css">
		#lblProductName{
			text-transform:capitalize;
		}
	
        #cphConteudo_divSeloDermaclub {
            cursor: default;
        }

            #cphConteudo_divSeloDermaclub:hover {
                cursor: pointer;
            }
    </style>
    <script type="text/javascript">

     

    </script>

     <!-- SCRIPT MAPPER CLEARSALE -->
                                                                    <script>
                                                                        (function (a, b, c, d, e, f, g) {
                                                                            a['CsdmObject'] = e; a[e] = a[e] || function () {
                                                                                (a[e].q = a[e].q || []).push(arguments)
                                                                            }, a[e].l = 1 * new Date(); f = b.createElement(c),
                                                                                g = b.getElementsByTagName(c)[0]; f.async = 1; f.src = d; g.parentNode.insertBefore(f, g)
                                                                        })(window, document, 'script', '//device.clearsale.com.br/m/cs.js', 'csdm');
                                                                        csdm('app', '7cca55c77d');
                                                                    </script>
                                                <!--FIM SCRIPT MAPPER CLEARSALE -->


                <!-- conteudo -->
            </div>
        </div>
        <!-- FIM ESTRUTURA -->
        <!-- FOOTER -->
        <div class="pre-footer row">
            <div class="wrapper full">
                <div class="col newsletter">
                    <h5 class="news-title">Newsletter!</h5>
                    <p class="news-sub-title"><span>Cadastre-se</span></p>
                    <p class="text">Fique por dentro de todas as nossas promoções e descontos exclusivos.</p>
                    <input type="email" class="input-email" placeholder="Digite seu email" id="txtnewslettermaster" />
                    <a class="btn btn-acqua" onclick="AdicionarNewsLetter(1)">OK</a>
                    <p id="NewsLetterMaster" class="textNewsLetter"></p>
                </div>
                <div class="col cvs">
                    <p align="center">
                        <img class="img-cvs-health" src="https://www.onofre.com.br/assets/img/cvs-health-logo-grande.jpg" alt="CVS Health" />
                    </p>
                    <p class="text">Desde 2013, a Drogaria Onofre faz parte da maior empresa de saúde do mundo, CVS Health. Com mais de 7.500 drogarias distribuídas por todo o território americano, e 47 no Brasil. </p>
                    <a href="/Institucional/Default.aspx?InstId=230" class="btn btn-red" title="Saiba mais sobre a CVS Health">CLique aqui</a>
                </div>
                <div class="col lojas last">
                    <div class="info">
                        <h5>Nossas Lojas</h5>
                        <p class="text">A Drogaria Onofre possui 47 lojas em todo o território nacional e oferece mais de 15 horas de atendimento farmacêutico por dia.</p>
                        <a href="/nossaslojas/nossaslojas.aspx" class="btn btn-blue" title="Veja mais lojas">Clique aqui</a>
                    </div>
                    <img src="https://www.onofre.com.br/assets/img/banner-nossas-lojas.jpg" alt="Conheça nossas lojas" />
                </div>
            </div>
            <!-- /wrapper prefooter -->
        </div>
        <!-- /prefooter -->
        <footer class="page-footer">
                                        <div class="page-footer-top row">
                                            <div class="wrapper">
                                                <div class="row top-items">
                                                    
                                                            <div class="col4">
                                                                <h5 class="box-title">Sobre a Onofre</h5>
                                                                <ul class="links-list">
                                                                    
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=93' target='' class="list-link">
                                                                                    Quem Somos
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/nossaslojas/nossaslojas.aspx' target='' class="list-link">
                                                                                    Nossas Lojas
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.vagas.com.br/onofre' target='' class="list-link">
                                                                                    Trabalhe Conosco
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/nossaspoliticas' target='' class="list-link">
                                                                                    Nossas Políticas
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=207' target='' class="list-link">
                                                                                    Imprensa
                                                                                </a>
                                                                            </li>
                                                                        
                                                                </ul>
                                                            </div>
                                                        
                                                            <div class="col4">
                                                                <h5 class="box-title">Serviços</h5>
                                                                <ul class="links-list">
                                                                    
                                                                            <li class="list-item">
                                                                                <a href='https://portal.anvisa.gov.br/wps/portal/anvisa/informetecnico/!ut/p/c5/04_SB8K8xLLM9MSSzPy8xBz9CP0os3hnd0cPE3MfAwMDMydnA093Uz8z00B_A3dTU6B8JE55A38jArrDQfbh1w-SN8ABHA30_Tzyc1P1I_WjzBGmuBtamBt4WribujmFOhsbhBnqR-akpicmV-oX5EYYZJmEKgIAztfaUw!!/dl3/d3/L2d' target='_blank' class="list-link">
                                                                                    Alertas e Informes Anvisa
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.cff.org.br/' target='_blank' class="list-link">
                                                                                    Conselho Federal de Farmácia
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://portal.cfm.org.br/' target='_blank' class="list-link">
                                                                                    Conselho Federal de Medicina
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=25' target='' class="list-link">
                                                                                    Aplicativo Onofre para iPhone e Android
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='/mapa-site' target='' class="list-link">
                                                                                    Mapa do Site
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://portalsaude.saude.gov.br/index.php/o-ministerio/principal/secretarias/sctie/farmacia-popular' target='_blank' class="list-link">
                                                                                    Farmácia Popular
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/entregaRapida/' target='' class="list-link">
                                                                                    Entrega Rápida
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=275' target='' class="list-link">
                                                                                    Monte sua farmacinha
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=28' target='' class="list-link">
                                                                                    Confira condições de frete
                                                                                </a>
                                                                            </li>
                                                                        
                                                                </ul>
                                                            </div>
                                                        
                                                            <div class="col4">
                                                                <h5 class="box-title">Relacionamento</h5>
                                                                <ul class="links-list">
                                                                    
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/CentralCliente/Default.aspx' target='' class="list-link">
                                                                                    Central do Cliente
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/FaleConosco/' target='' class="list-link">
                                                                                    Fale Conosco
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/centralajuda/centralajuda.aspx' target='' class="list-link">
                                                                                    Central de Ajuda
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/falefarmaceutico/' target='' class="list-link">
                                                                                    Fale com o Farmacêutico
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://blog.onofre.com.br/' target='' class="list-link">
                                                                                    Blog da Onofre
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=97' target='' class="list-link">
                                                                                    Troca e Devolução
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://chat_online' target='' class="list-link">
                                                                                    Chat Online
                                                                                </a>
                                                                            </li>
                                                                        
                                                                </ul>
                                                            </div>
                                                        
                                                    <div class="col4 apps last">
                                                        <h5 class="box-title">Aplicativo Onofre</h5>
                                                        <p>Baixe os nossos aplicativos e tenha nossas ofertas na palma da mão</p> <span>Baixar Apps</span> <a href="https://www.onofre.com.br/Institucional/Default.aspx?InstId=25" target="_blank" class="app-link apple">Apple</a> <a href="https://www.onofre.com.br/Institucional/Default.aspx?InstId=25" target="_blank" class="app-link android">Android</a> </div>
                                                </div>
                                                <div class="row bottom-items">
                                                    <div class="col8">
                                                        <h6>Compre pelo telefone</h6>
                                                        <div class="tel">
                                                            <p>4007-2526</p>
                                                            <span>(Custo de uma ligação local)</span><br />
                                                            <span>Horário das 8h às 21h, de segunda a sábado</span>
                                                        </div>                                                        
                                                        <div class="tel" style="float:right" >
                                                            <p>0800-609-3030</p> <span>Demais localidades</span> 
                                                        </div>
                                                    
                                                        <div class="col8" style="margin: 10px 0px 0px 0px"> Caro cliente, a Drogaria Onofre informa que, temporariamente, os pedidos realizados no site após às 21h de sábado serão processados na segunda-feira, a partir das 8h. Desta forma, ressaltamos que o prazo de entrega da sua compra
                                                            <br> será calculado a partir desta data. </div>
                                                    </div>
                                                    <div class="col5 social">
                                                        <h6>Acompanhe a Onofre</h6>
                                                        <ul class="social-links">
                                                            <li class="social-item"><a class="social-link facebook" href="https://www.facebook.com/DrogariaOnofreOficial" class="social-link facebook" target="_blank" title="Facebook">Facebook</a></li>
                                                            
                                                                <li class="social-item"><a href="https://www.instagram.com/drogariaonofre/" class="social-link instagram" target="_blank" title="Instagram">Instagram</a></li>
                                                                <li class="social-item">
                                                                    <a href="https://blogonofre.wordpress.com" target="_blank"> <img src="https://www.onofre.com.br/assets/img/be-onofre-logo.jpg" alt="Be onofre" /></a>
                                                                </li>
                                                        </ul>
                                                    </div>
                                                </div>
                                            </div>
                                            <!-- /wrapper page-footer-top -->
                                        </div>
                                        <!-- /page-footer-->
                                        <div class="page-footer-bottom row">
                                            <div class="wrapper">
                                                <div class="col8">
                                                    <p class="title-box">Formas de pagamento</p> <img class="img-formas-pagamento-master" src="https://www.onofre.com.br/assets/img/formas-de-pagamento.jpg" alt="Visa, MasterCard, Amex, Diners, Hipercard, Aura e Boleto bancário" /> </div>
                                                <div class="col5 seguranca">
                                                    <p class="title-box">Segurança</p>
                                                    <ul class="selos">
                                                        <li>
                                                            <a id="seloEbit" href="https://www.ebit.com.br/onofre-em-casa" target="_blank" onclick="redir(this.href)" style="background-image: url(&quot;https://a248.e.akamai.net/f/248/52872/0s/img.ebit.com.br/ebitBR/selo/img_973.png&quot;); width: 89px; height: 95px; display: block; overflow: hidden; position: relative; float: left" title="Avaliado pelos consumidores"></a>
                                                        </li>
                                                        <li>
                                                            <!-- COMODO -->
                                                            <script language="javascript" type="text/javascript">
                                                                /*<![CDATA[*/
                                                                var tl_loc0 = (window.location.protocol == "https:") ? "https://secure.comodo.net/trustlogo/javascript/trustlogo.js" : "https://www.trustlogo.com/trustlogo/javascript/trustlogo.js";
                                                                document.writeln('<script language="JavaScript" src="' + tl_loc0 + '" type="text/javascript"><\/script>'); /*]]>*/
                                                            </script>
                                                            <!-- COMODO -->
                                                            <script language="JavaScript" type="text/javascript">
                                                                TrustLogo("https://www.onofre.com.br/img/Rodape/comodo.png", "SC5", "none");
                                                            </script>
                                                        </li>
                                                    </ul>
                                                </div>
                                            </div>
                                            <!-- /wrapper page-footer -->
                                        </div>
                                        <!-- /page-footer-bottom -->
                                        <div class="row">
                                            <div class="wrapper"> <address class="col16"> <span id="lblDescriptionAddress"><p align="center"><span style="color: #888888;">Drogaria Onofre Ltda | CNPJ 61.549.259/0013-14 | IE 115.276.053.114 | Av. da Liberdade, 902 Complemento 904 - Liberdade | São Paulo (SP) | Horário de funcionamento: Segunda a Domingo 07:00 às 22:00 | CEP: 01502-001 | Telefone 4007-2526</span><br /><span style="color: #888888;">Farmacêutico Responsável: Dra. Thais Briotto de Andrade dos Santos | CRF - SP: 53.912 | AFE: 7.46544-5 | CMVS: 35503080147700867012</span></p>
<p align="center"><span style="color: #888888; font-family: tahoma, arial, helvetica, sans-serif; font-size: x-small;">As informações contidas neste site não devem ser usadas para automedicação e não substituem, em hipótese alguma, as orientações dadas pelo profissional da área médica. Somente o médico está apto a diagnosticar qualquer problema de saúde e prescrever o tratamento adequado. Ao persistirem os sintomas, o médico deverá ser consultado. Os preços e promoções divulgados no site são válidos apenas para compras feitas pela Internet e podem variar conforme região de entrega. Em caso de divergência, o preço válido é o do carrinho de compras. Imagens meramente ilustrativas. Este site é melhor visualizado na configuração 1024x768.</span><br /><span style="color: #888888; font-family: tahoma, arial, helvetica, sans-serif; font-size: x-small;">Copyright © 1999 - 2016 Onofre em Casa. Todos os direitos reservados.</span><br /><span style="color: #888888; font-family: tahoma, arial, helvetica, sans-serif; font-size: x-small;">*Desconto não válido para todos os produtos dessa página</span></p></span> </address>
                                                 </div>
                                        </div>
                                        <!-- /wrapper copyright -->
                                        </div>
                                        <div id="armored_website">
                                            <param id="aw_preload" value="true" /> </div>
                                        <script type="text/javascript" src="//selo.siteblindado.com/aw.js"></script>
                                        <!-- /copyright -->
                                    </footer>
        <!-- /page-footer -->
        <!-- FIM FOOTER -->
        
    </form>
    <!-- Script Chat online-->
    <script>
        var chat_online = $("a[href='https://chat_online']").removeAttr("href");
        chat_online.click(function (event) { window.open("https://onofre.custhelp.com/app/chat/chat_launch", "Chat Online Drogaria Onofre", "top=80,left=900,width=475,height=715"); });
    </script>
    <!--END chat online -->


    <!-- ------------------------------------------------------------------------------------------------------------- -->
    <!-- -------------------------------------------------- SCRIPTS -------------------------------------------------- -->
    <!-- ------------------------------------------------------------------------------------------------------------- -->
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//www.googletagmanager.com/ns.html?id=GTM-5SFH26" height="0" width="0" style="display: none; visibility: hidden"></iframe>
    </noscript>
    <script>
        /*<![CDATA[*/
        (function (f, d, l, i, n) {
            f[i] = f[i] || [];
            f[i].push({
                "gtm.start": new Date().getTime(),
                event: "gtm.js"
            });
            var j = d.getElementsByTagName(l)[0],
                o = d.createElement(l),
                p = i != "dataLayer" ? "&l=" + i : "";
            o.async = true;
            o.src = "//www.googletagmanager.com/gtm.js?id=" + n + p;
            j.parentNode.insertBefore(o, j)
        })(window, document, "script", "dataLayer", "GTM-5SFH26"); /*]]>*/
    </script>
    <!-- End Google Tag Manager -->
 


      <script>

          var AbertoLoginBox = false;


          function ExibirPopupLogin(a, b, c) {
              $.colorbox({
                  href: a,
                  open: !0,
                  iframe: !0,
                  scrolling: !0,
                  opacity: .5,
                  overlayClose: false,
                  transition: "fade",
                  height: c,
                  width: b,
                  fixed: !0,
                  closeButton: true,
                  className: "colorbox_login",

              });

              AbertoLoginBox = true;

              $(document).bind('cbox_complete', function () {

                  $("#cboxClose").hide();
                  $("#cboxClose").html("X");
                  $("#cboxClose").attr("class", "fecharBoxLogin");
                  $("#cboxClose").css("text-indent", "0px")
                  $("#cboxClose").css("text-indent", "0px")
                  $("#cboxClose").css("border", "2px solid rgb(216, 216, 216)")
                  $("#cboxClose").css("background-color", "white")
                  $("#cboxClose").css("color", "rgb(216, 216, 216)")
                  $("#cboxClose").css("top", "2px")
                  $("#cboxClose").css("right", "2px")                 
                  $("#cboxClose").show();

                  $("#cboxClose").click(function () {

                      $.colorbox.close();

                  });

                 
              }); 

          }

      </script>
      <script type="text/javascript">

        setTimeout(function () {
            var url = "../../../Jss/Colorbox/jquery.colorbox-min.js";
            $.getScript(url, function () {
                console.log("jquery.colorbox-min Carregado!");
            });
        },1300);

    </script>
    
    <!-- ------------------------------------------------------------------------------------------------------------- -->
    <!-- -------------------------------------------------- SCRIPTS -------------------------------------------------- -->
    <!-- ------------------------------------------------------------------------------------------------------------- -->
     
</body>
<link href="assets/css/chaordic.css" rel="stylesheet" />


</html>
